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ABSTRACT 
 
 Medication non-adherence and non-persistence are pressing issues in healthcare today. 
Their resultant health and economic ill-effects are well studied in numerous diseases. To help 
improve medication adherence and persistence, their effective and efficient measurement is 
essential. Thus, the purpose of this dissertation was to develop the Medication Non-Adherence 
Scale (MNAS) and the Medication Non-Persistence Scale (MNPS). 
The scales were administered to patrons of three independent community pharmacies in 
the Southeastern United States. Their responses were anonymously linked to prescription fill 
data. The MNAS was validated against the past 6 months of prescription fill data, while the 
MNPS against the past 12 months. The MNAS was also tested against 3 months of prospective 
data to study its ability to predict future non-adherence. 
 Confirmatory factor analyses offered evidence for internal consistency reliability, and 
convergent and discriminant validity. The results indicated a 5 factor solution for the MNAS – 
worries about side-effects, worries about addiction, worries about cost, lack of perceived need, 
and unintentional non-adherence – and a single factor solution for the MNPS. Linear regression 
analyses concluded that the scales demonstrated concurrent validity (MNAS: unstandardized 
regression coefficient=-0.50 (p<0.001); MNPS: unstandardized regression coefficient=-3.97 
(p=0.03)). Another linear regression analysis also offered evidence for the MNAS having 
predictive validity (unstandardized regression coefficient=-0.62 (p<0.001)). ROC curve analysis 
iii 
 
suggested that a score of greater than 16 on the MNAS indicated non-adherence in the past 6 
months, and a score of greater than 20 indicated non-adherence in the next 3 months. A score of 
1 or higher on the MNPS indicated non-persistence in the past 12 months. 
 The MNAS was seen to perform better than the Medication Adherence Reasons Scale 
(MAR-Scale: R2=0.016, standardized regression coefficient=-0.125; MNAS: R2=0.043, 
standardized regression coefficient=-0.208) and the 1986 Morisky scale (R2=0.018, standardized 
regression coefficient=-0.134) in estimating concurrent PDC, and better than the Adherence 
Estimator (AE: R2=0.010, standardized regression coefficient=-0.099; MNAS: R2=0.083, 
standardized regression coefficient=-0.288) in estimating future PDC. These estimates were also 
statistically significantly different from each other. 
 Thus, the MNAS and MNPS help fill vital gaps in adherence and persistence 
measurement, and may be used by healthcare practitioners and researchers to improve patient 
health.  
iv 
 
DEDICATION 
 
 This dissertation is dedicated to the people of Mississippi who took the time to respond to 
my survey. You are awesome.  
v 
 
LIST OF ABBREVIATIONS AND SYMBOLS 
 
Abbreviation Description 
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ARB Angiotensin-receptor blocker 
ASK-20 Adherence Starts and Knowledge-20 
AVE Average variance extracted 
BARS Brief Adherence Rating Scale 
BB Beta-blockers 
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MEMS Medication Event Monitoring System 
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MID Unique mailing identifier 
MMAS Morisky Medication Adherence Scale 
MNAS Medication Non-Adherence Scale 
MNAS-I-Addiction Intentional non-adherence due to worries about addiction 
to the medication 
MNAS-I-Cost Intentional non-adherence due to worries about cost of 
the medication 
MNAS-I-Perceived need Intentional non-adherence due to lack of perceived need 
of the medication 
MNAS-I-Side-effects Intentional non-adherence due to worries about side-
effects 
MNAS-U Unintentional non-adherence 
MNPS Medication Non-Persistence Scale 
MPR Medication possession ratio 
MUAH Maastricht Utrecht Adherence in Hypertension 
NCQA National Committee for Quality Assurance 
NICE National Institute of Health and Clinical Excellence 
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PTID Unique patient identifier 
RAM Reported Adherence to Medications 
ROC Receiver-operating characteristic 
WLSMV Weighted least squares with mean and variance 
adjustment 
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BACKGROUND 
 
Importance of Studying Medication Adherence and Medication Persistence 
It has been estimated that 30-60% of prescribed medicines are not taken as directed.1,2 
Such behaviors usually involve medication non-adherence or medication non-persistence.2,3,* 
Numerous studies have demonstrated the resultant ill-effects of these behaviors. For example, Ho 
and colleagues identified the adverse effects of non-adherence to medications used to treat 
diabetes mellitus on all-cause hospitalizations and all-cause mortality.4 Studies have also shown 
that discontinuation of relevant medication therapy post myocardial infarction (i.e. aspirin, β-
blockers, and statins) can lead to a statistically significant increase in mortality.5 Sokol et al. 
concluded that patients with diabetes mellitus, hypertension, hypercholesterolemia, or congestive 
heart failure who were non-adherent to their medications had statistically significantly greater 
hospitalizations. Such behavior was also observed to lead to higher overall health care costs.6 
According to the 2011 Express Scripts Drug Trend Report, an excess of $317.4 billion may have 
been spent due to medication non-adherence in that year.7 Due to these reasons, such behaviors 
have been referred to as “the ‘other’ drug problem”.8 In order to counter this issue, effective and 
efficient measurement of medication adherence and persistence is necessary. 
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Measurement of Medication Adherence 
Medication adherence has been operationalized in multiple ways. Some of the often used 
methods are described below. 
Direct patient observation. In this method, as the title suggests, patients are directly observed 
while taking their medications. Such a technique is direct and objective.9,10,† This is often 
considered the ideal method to measure medication adherence, but when used in the outpatient 
setting or in large studies, its practicality has been questioned.9,11 Also, as pointed out by 
Garfield et al.12, and Osterberg and Blaschke9, intentionally non-adherent patients may “hide 
pills in the mouth and then discard them.” This may lead to a bias in classification of individuals 
as adherent or non-adherent. 
Drug level in biological fluids / biological assays and biomarkers. These methods detect the 
presence of the drug, an associated metabolite, or the biomarker in a biological fluid. In the case 
of biomarkers, markers are added to the biological fluids in order to detect the presence of the 
drug or associated metabolites.11 The advantage of these methods is that they are direct and 
objective techniques of estimating medication adherence9,10 But using these methods on a routine 
basis is difficult. Also, as mentioned by Farmer11, these method do not measure patients’ actual 
medication-taking behavior; despite having the required level of the drug or associated 
metabolite in the biological fluids, the patient may not have consumed the medication as 
directed. Thus, there is little evidence to suggest that the patient will follow medication-taking 
directions in the future.11 
Pill counts. This is one of the most commonly used methods to measure medication adherence in 
clinical trials.13 It is also used in clinical practice.11 Pill counts are considered to be objective and 
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indirect measures of medication adherence9,10 This method involves counting the number of 
dosage units (tablets, capsules, etc.) that are not consumed by a patient at the time of the 
scheduled check. The percentage of compliance is then calculated by dividing the number of 
dosage units consumed by the expected number of dosage units that should have been consumed 
(taking the number of units prescribed and the days’ supply into consideration), and multiplied 
by 100. Despite its relative simplicity, it has a severe disadvantage – patients may discard their 
dosage units prior to the scheduled check to appear more adherent (e.g. pill dumping). Thus, pill 
counts often overestimate adherence behavior.14–17 
Prescription refill records and administrative claims data. The use of these data sources in 
the measurement of medication adherence has increased drastically with the availability of drug 
insurance claims data.11,18–22 Proportion of days covered (PDC) and medication possession ratio 
(MPR) have been identified as the most appropriate measures of medication adherence using 
administrative claims data.23–26 These methods are considered objective but indirect.9,10 The 
formulae for measuring PDC and MPR have been given below.26–29 
MPR = 
Sum of the days supply for all fills of the drug in the study period
Number of days in the study period
 
PDC = 
Number of days the patient is covered by the drug in the study period
Number of days in the study period
 
 PDC offers a more conservative estimate.29 The calculation of PDC takes potential 
overlaps and gaps in therapy into consideration. Although either of these methods is accepted in 
pharmacoepidemiology, pharmacoeconomics, and health outcomes research, some limitations 
exist. While using prescription records as a surrogate of medication-taking behavior, the 
researcher must make a few assumptions – the data are complete, i.e. all the necessary variables 
and records are present11, and a prescription fill indicates that the medication was consumed.9 
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But in reality, unless the data were obtained from a closed system (e.g., a nationalized health care 
system) there may be individuals who have obtained a prescription fill from a source other than 
the one available to the researcher (other pharmacy, other health care insurer, etc.), and a 
prescription fill may not indicate that the medication was consumed.9 Being cognizant of these 
assumptions and taking possible steps to prevent invalidation of obtained values is essential. 
Electronic monitoring. Electronic monitoring of medication adherence is done by implementing 
devices that have a microchip built into them. These are classified as objective, but indirect 
methods.9,10 An example of such devices is the Medication Events Monitoring System (MEMS) 
cap.14 This is a special prescription bottle cap that collects data every time it is opened. The 
numbers reported by the MEMS cap can be accurate down to the second at which the cap was 
opened. This device can help collect continuous, and relatively reliable data.11,14,30 The MEMS 
caps have been used to measure medication adherence in numerous studies.14,31–36 Their 
successful empirical performance has often resulted in them to being called the “gold standard” 
measure of medication adherence.14,30,37 They, however, have some drawbacks. Firstly, they are 
expensive and cumbersome; they require a visit to the location where the data are being collected 
for downloading information. Secondly, and perhaps more importantly, they measure the times 
when the bottles were opened and not when the medication was consumed. If a patient simply 
opens and shuts the cap (unintentionally, or otherwise), a datum is recorded. This could 
adversely affect medication adherence measurement.11,12,38 
Self-reporting. Broadly, there are three types of patient self-reporting methods – patient diaries, 
patient interviews, and questionnaires.11 In the case of patient diaries, patients are asked to 
maintain a diary to record their daily medication-taking behavior. Patient interviews are 
unstructured, potentially unstandardized and non-validated interviews conducted to obtain 
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medication adherence-related information from patients. On the other hand, questionnaires are 
structured, standardized, and often formally tested for their psychometric properties. They are 
used to obtain empirical data about medication adherence from patients.11 Self-reporting has 
often been criticized for offering less reliable and valid estimates of medication adherence.15,19,39–
41 These methods cannot be classified as objective or direct.9,10 Despite this, the National 
Collaborating Centre for Primary Care and the Royal College of General Practitioners (London, 
UK), along with National Institute of Health and Clinical Excellence (NICE) commended these 
measures as being the most appropriate for monitoring medication adherence in clinical 
practice.12,42 The primary reason for this is their feasibility, practicality, and simplicity.9,11,43 In a 
clinical setting, other, potentially more valid, reliable, and objective measures such as MEMS, 
bioassays, biomarkers, prescription refill records, pill counts, etc. are often considered 
impractical and expensive.12 Such a setting requires an instrument that is quick and easy to 
administer, and gives immediate results. Only a self-reported questionnaire is capable of such a 
task.12 Moreover, a recent review by Shi and colleagues concluded that self-reported measures 
demonstrate moderate to high correlation with electronically monitored measures of medication 
adherence, further strengthening the evidence of the capability for these measures.44 Thus, a self-
reported scale is the preferred choice for a health care practice setting administrable measure of 
medication non-adherence.  
 
Need for a Better Medication Adherence Scale 
Disease non-specificity. Currently, the 1986 Morisky scale is the most widely used self-reported 
measure of medication adherence in the clinical setting.45 Although commonly used, data 
supporting its use offer mixed results. Some studies have reported low internal consistency 
7 
 
reliability, while others report acceptable levels.33,45–49 The primary reason for its popularity is its 
ability to be used as a disease non-specific instrument.33,46,48–50 Although the scale was developed 
in hypertensive patients, it has yielded similar results in other disease conditions.33,46,48,49 The 
Morisky scale was updated in 2009 to improve upon its internal consistency.51 The Morisky 
Medication Adherence Scale (MMAS) has twice the number of items (as compared to the 1986 
version)‡, and to the best of our knowledge, has only been tested among hypertensive and 
diabetic patients.51–55 In 1999, Horne et al. published the Reported Adherence to Medication 
(RAM) scale.56 Although this scale too has been used in multiple disease conditions, it has not 
been found to report beyond moderate psychometric properties.49,56,57 Another drawback of this 
scale is that it uses different units of measurement for half of its items.56 This may lead to 
difficulties in its interpretation; an important property in a practice setting. 
Distinguishing between different reasons for medication non-adherence. In their recent 
systematic review, Garfield et al. stated the need for a better disease non-specific measure of 
medication adherence.12 In doing so, they outlined three desirable characteristics of such a scale 
– pragmatic (inexpensive, short, non-intrusive, and flexible to the mode of administration), 
having good psychometric properties (reliable, valid, sensitive, and specific), and having a sound 
theoretical foundation (use of an appropriate theory).12 A theoretical foundation is essential. But 
using an appropriate theory is even more important. Virtually every health behavior theory has 
been tested in the context of medication adherence – social learning theory/social cognitive 
theory, theory of reasoned action/theory of planned behavior, health belief model, 
transtheoretical model, etc. – albeit offering inconsistent results.58–62 Garfield and colleagues 
argue that the reason for such results is that these theories assume that the medication non-
adherence behavior was intentional.12 They, along with many others in recent years, suggest that 
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it is important to distinguish between intentional and unintentional non-adherence.43,50,57,63–69,§ 
Such a classification can help in distinguishing between the reasons for non-adherence. 
Usually, the purpose of measuring medication adherence in a clinical setting is to 
intervene and improve it. The underlying rationale for non-adherence is very different in the case 
of intentional and unintentional non-adherers. Thus the intervention techniques needed to 
improve medication adherence are different as well.12 In the case of intentional non-adherence, 
intervention strategies may focus on the physician-patient relationship, implementation of 
behavioral strategies (using e.g. health behavior models), etc.43,58,67,70 While in the case of 
unintentional non-adherence, strategies such as pill-boxes, reminder phone calls, text messages, 
emails, etc. would be more beneficial.12,68,** Studies have used existing scales to distinguish 
between these two forms of non-adherence. Some studies have used the 1986 Morisky scale, 
while others have used the RAM scale.45,50,56,69,††,‡‡ A recent study by Krousel-Wood and 
colleagues recommends the used of the Morisky Medication Adherence Scale (MMAS) for this 
purpose.55 However, as mentioned earlier, this scale has not been tested outside hypertensive and 
diabetic patients.51–55 Thus, its applicability is limited. 
Garfield et al. recommended the use of the model of accident causation proposed by 
Reason§§ to help distinguish between intentional and unintentional medication non-
adherence.12,63,64,71,72 Barber adapted Reason’s framework to the context of medication non-
adherence.63,***,††† According to this model, unintentional non-adherence can be a result of a 
‘slip’ or a ‘lapse’, where a slip is an outcome of lack of attention (e.g. taking the wrong dose, 
taking the wrong pill, etc.), and lapse, a “failure of memory” (e.g. forgetting to take a dose, 
forgetting that a dose has already been taken, etc.).63 Intentional non-adherence can be a result of 
a ‘mistake’ or ‘violation’. Mistakes are correct actions that have gone awry. They are further 
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separated into ‘rule-based mistakes’, and ‘knowledge-based mistakes’. Rule-based mistakes 
occur when a patient either incorrectly applies a good rule, or correctly applies a bad rule to 
tackle a particular scenario (e.g. stopping treatment with a non-addictive drug due to the fear of 
the possibility of getting addicted to it). Knowledge-based mistakes occur when no pre-existing 
rule applies to the situation at hand, and the patient must apply his/her knowledge (e.g. rather 
than getting a prescription refill immediately after a prior fill runs out unexpectedly, the patient 
decides against this being an emergency and delays this task).63 Violations, on the other hand, are 
“deliberate deviations from safe practice” (e.g. choosing not to pick up a prescription as the 
patient feels that the physician did not pay heed to his/her comments, not following the dosage 
regimen directed by the physician and taking all medications together rather than at separate 
times, etc.).63 
 Arguing against the use of this binary categorization of non-adherence, Unni and Farris 
developed the Medication Adherence Reasons Scale (MAR-Scale).73,74 They suggest that the 
intentional-unintentional classification limits the ability to identify specific reasons for non-
adherence.74 In the recently modified version of their scale, they categorized the reasons for non-
adherence as having four factors – practicality issues (e.g. not being able to open the container, 
pharmacy being out of medicine, etc.), lack of necessity belief issues (e.g. perceived need for 
medication, perceived effectiveness of medication, etc.), forgetfulness issues, and concern belief 
issues (e.g. possible side-effects or long-term effects). This classification was developed based 
on the Anderson’s Behavioral Model75, Leventhal et al.’s Common-Sense Model76,77, and the 
data collected in their study73. The items in the MAR-Scale were based on the conclusions 
reached by a systematic review conducted by Vik et al.10, and other studies pertaining to 
medication non-adherence.78–82 
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Estimation of health care quality. The Pharmacy Quality Alliance (PQA) considers medication 
adherence as an essential component of medication-use quality.83 They recommend the use of 
proportion of days covered (PDC) to measure medication adherence. Specifically, they 
recommend calculation of medication adherence for seven therapeutic classes outlined by the 
National Committee for Quality Assurance (NCQA) – beta-blockers (BBs), angiotensin-
converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), calcium channel 
blockers (CCBs), biguanides, sulfonylureas, thiazolidinediones, and statins.84 PDCs are also used 
by the Centers for Medicare & Medicaid Services (CMS). Their current guidelines use measures 
of medication adherence to determine bonus payments to capitated medicare advantage plans.85 
 The problem with PDCs is that they can only be calculated on retrospective data. 
Considering their importance, it is necessary to develop a scale that can provide a self-reported 
estimate of the PDC. Such a scale may help health care practitioners assess the quality of care 
being provided prior to the analysis of retrospective prescription fill data. Our literature review 
did not identify any disease non-specific self-reported measures of medication non-adherence 
that have been tested to estimate concurrent PDCs. 
Thus, there is a need for a psychometrically-sound, self-reported measure of medication 
non-adherence, which is disease non-specific, theory-based, capable of distinguishing between 
the different reasons for non-adherence, and provides an estimate of the PDC measure. 
 
Measurement of Medication Persistence and Need for a Self-Reported Instrument 
Medication persistence is usually operationalized as the duration of time from initiation 
to discontinuation of therapy, after accounting for therapeutically permissible gaps.3,23,28,84,86 This 
requires the use of prescription claims, pharmacy refill, pill counts, or clinical trials data.3,23,87,88 
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According to our review of the literature, currently, there are no multi-item self-reported 
measures of medication persistence in the scientific literature or health care practice that have 
been validated and tested for their reliability. But due to numerous issues with stopping 
pharmacotherapy without the consent of a health care provider, it is necessary to develop an 
instrument that can help identify patients who have been non-persistent with their medications, 
and the reasons behind such behavior.5,23 Thus, the development of such a self-reported measure 
is pertinent. 
 
Predicting Future Medication Adherence 
Along with the assessment of concurrent medication adherence, estimating future non-
adherence behavior is often of value to health care practitioners and researchers alike. Several 
self-reported instruments have been developed to aid in the identification of patients who have a 
higher propensity of being non-adherent to prescription medications.89–114 The authors identified 
five measures that have been developed for, or validated in, multiple chronic diseases – the 
Adherence 14 (A14) scale93, the Adherence Starts and Knowledge-20 (ASK-20) scale99, the 
Medical Adherence Measure (MAM)106, the Beliefs and Behaviour Questionnaire (BBQ)111, and 
the Adherence Estimator (AE)112–114. Out of these, only the AE has been tested for its predictive 
validity using prospective pharmacy claims data.113 The AE is a 3-item instrument used to assess 
“proximal beliefs related to intentional non-adherence.”113 These items assess the patients’ 
perceived importance of their prescription medication(s), worries about potential side/adverse 
effects, and perceived financial burden. This instrument has presented good psychometric 
properties and has been shown to successfully predict future medication non-adherence.112–114 
However, due to its focus on intentional medication non-adherence, the prediction of potential 
12 
 
unintentional medication non-adherence is left unaddressed. Thus, development of a scale that 
can predict a wider scope of future non-adherence behaviors is necessary.
13 
 
SPECIFIC AIMS 
 
As mentioned in the prior section, medication non-adherence and non-persistence are 
important issues in health care.1,2,4–7 Despite this, there are numerous gaps in the measurement of 
these constructs.12 This dissertation sets forth the following specific aims to bridge such gaps in 
the literature: 
Paper 1: To develop two self-reported measures – the Medication Non-Adherence Scale 
(MNAS) and the Medication Non-Persistence Scale (MNPS) 
o The MNAS will be a health care practice setting administrable, disease non-
specific measure of medication non-adherence with the ability to distinguish 
between the different reasons for non-adherence, and provide a self-reported 
estimate of the proportion of days covered (PDC) measure23,26–29 
o The MNPS will be a health care practice setting administrable, disease non-
specific measure of medication non-persistence. 
Paper 2: To test the ability of the MNAS in predicting objectively measured future 
medication non-adherence (i.e., using PDCs)  
Paper 3: To compare the abilities of the MNAS and other relevant scales in predicting 
objectively measured medication non-adherence; specifically: 
o  To compare the ability of the MNAS, the 1986 Morisky scale, and the MAR-
Scale in predicting objectively measured concurrent medication non-adherence 
(i.e., using PDC) 
14 
 
o To compare the ability of the MNAS and the Adherence Estimator®xi in 
predicting objectively measured future medication non-adherence (i.e., using 
PDC)27,112–115 
15 
 
SIGNIFICANCE 
 
Medication Non-Adherence Scale (MNAS) 
This dissertation is concerned with the development of two self-reported measures, the 
first of which is the Medication Non-adherence Scale (MNAS). This scale was designed to offer 
the following properties: 
 Health care practice setting administrable 
 Disease non-specific 
 Ability to distinguish between the different reasons for non-adherence 
 Provide a self-reported estimate of the proportion of days covered (PDC) measure 
 Predict future medication non-adherence 
Although, as discussed in earlier sections, many of the current self-reported scales 
possess some of the properties mentioned above, our literature review did not reveal any measure 
that bore all of these properties. Thus such a scale may offer multiple benefits to health care 
practitioners and researchers. 
 
Medication Non-Persistence Scale (MNPS) 
This dissertation is also concerned with the development of the Medication Non-
Persistence Scale (MNPS). As addressed earlier, this will be the first multi-item self-reported 
measure of medication persistence in contemporary scientific literature. Development of the
16 
 
MNPS may offer health care practitioner and researchers a much needed insight into the reasons 
behind medication non-persistence.
17 
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* The literature refers to four terms in the area of medication-taking behaviors – adherence, compliance, persistence, 
and concordance.1–3 One is often confused for the other. Concordance, a term more prominent in the United 
Kingdom, is used to denote a “therapeutic alliance” between the health care practitioner and the patient.1,116 It 
embodies the epitome of contemporary patient-centered care. Although often classified as a medication-taking 
behavior, Horne and colleagues state that it paints a more normative picture.2 Persistence refers to taking ones 
medications long-term, continually.88 It is also defined as the amount of time that a patient follows the prescribed 
treatment regimen.3 If a patient follows the prescribed therapy (after accounting for therapeutically permissible 
gaps), he/she is said to be persistent. Adherence and compliance are often used interchangeably. There are however, 
subtle differences. Compliance assumes that the patient is merely, and passively, following the health care 
practitioner’s “orders”, while adherence considers the patient in a more active role (takes medication, follows diet, 
brings about lifestyle changes, etc.).1,2,117 In today’s world of patient-centered care, the term ‘adherence’ is generally 
preferred by health care practitioners as ‘compliance’ may suggest oppression or order-following.1,9 Thus in this 
dissertation, the term ‘adherence’ will be used to depict this type of medication-taking behavior. 
† Two types of classifications of methods for measuring medication adherence are most commonly found in the 
literature – direct versus indirect9,11, and objective versus subjective10. Direct methods purport to measure actual 
medication adherence (e.g. by direct patient observation, or biological assays and biomarkers), and are said provide 
“proof” of adherence11, while indirect measures use surrogates such as prescriptions filled, opening of prescription 
bottle cap, pills remaining, etc.9 Self-reported measures are considered to be subjective measures, while all other 
methods discussed here are considered to be objective. This distinction has been made on the premise that responses 
to self-reported measures may be affected by issues like social desirability bias118, making them more ‘subjective’.10 
‡ As emphasized by Garfield and colleagues in their recent review, when the purpose of the instrument is 
administration in a clinical setting, the length of the instrument is important.12 Thus, shorter the instrument, lesser 
the time spent by the health care practitioner on adherence assessment. 
§ A point to note here is that the use of the term ‘adherence’ (or ‘non-adherence’) implies that the patient plays a 
more active role in medication-taking behavior. It is this assumption of an active role that enables the possibility of 
intentional medication non-adherence. If a patient were assumed to play a passive role in medication-taking (i.e. 
along the lines of ‘compliance’), the distinction between the intentionality of such behavior would have been 
virtually impossible 67,68. 
** Contrary to this, Unni and Farris119 concluded that in the case of Medicare enrollees, “concern beliefs” in 
medications were a significant predictor of unintentional non-adherence. Their operationalization of unintentional 
non-adherence was based on the 1986 Morisky scale. They recommend that this finding demands further study. 
†† For the 1986 Morisky scale: two items are used to represent intentional non-adherence (“When you feel better do 
you sometimes stop taking your medicine?”, “Sometimes if you feel worse when you take the medicine, do you stop 
taking it?”), and two for unintentional non-adherence (“Do you ever forget to take your medicine?”, “Are you 
careless at times about taking your medicine?”) 50. 
‡‡ For the RAM: the item used to measure intentional non-adherence is: “Some people […] say that they miss out a 
dose of their medication or adjust it to suit their own needs. How often do you do this?” While the item used to 
measure unintentional non-adherence is: “Some people forget to take their medicine. How often does this happen to 
you?” 
§§ This framework has also been called the ‘accident causation framework’ and the ‘human error theory’.12,63,64 
*** Barber named his adaptation of the model, ‘medical error theory’. 
††† ‘Non-adherence’ has been termed ‘non-compliance’ in Barber’s 2002 adaptation of the model of accident 
causation, but based on Lehane and McCarthy’s arguments, and to be consistent with the rest of this research 
proposal, we will continue referring to this medication-taking behavior as non-adherence.63,67,68 
xi Adherence Estimator is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 
Whitehouse Station, NJ, USA. US and non-US Patents Pending. Copyright © 2008 Merck Sharp and Dohme Corp., 
a subsidiary of Merck & Co., Inc. All rights reserved. 
                                                          
40 
 
 
 
 
 
 
 
 
 
 
CHAPTER II:  
PAPER 1 
DEVELOPMENT OF THE MEDICATION NON-ADHERENCE SCALE (MNAS) AND THE 
MEDICATION NON-PERSISTENCE SCALE (MNPS) 
 
 
 
 
 
 
 
 
In preparation for Medical Care 
Format adapted for dissertation
41 
 
ABSTRACT 
 
Background 
Although there are numerous self-reported measures of medication non-adherence in the 
scientific literature, no single measure has demonstrated evidence of having good psychometric 
properties, being disease non-specific, distinguishing between the different reasons for non-
adherence, and offering an estimate of the proportion of days covered (PDC) measure. Also, 
there is no multi-item self-reported measure of medication non-persistence in the scientific 
literature or health care practice. 
Objectives 
To develop two self-reported measures – the Medication Non-Adherence Scale (MNAS) and the 
Medication Non-Persistence Scale (MNPS) 
Research Design 
A cross-sectional survey containing the MNAS and the MNPS was administered to patrons of 
three independent community pharmacies. The patients’ survey responses were linked with their 
prescription fill data to study the internal consistency reliability, and convergent, discriminant 
and concurrent validity of the scales being developed. 
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Subjects 
A total of 685 patrons of three independent community pharmacies located in the Southeastern 
region of the US were included in the sample for analysis involving the MNAS, and 675 for 
analysis involving the MNPS. 
Measures 
The MNAS assessed the extent and reasons for non-adherence, and the MNPS assessed the 
reasons for non-persistence. PDC was used as the criterion measure of validating the MNAS, 
while ‘days to discontinuation’ performed this function in the case of the MNPS. 
Results 
The MNAS presented with a five factor solution – Intentional non-adherence due to worries 
about side-effects, intentional non-adherence due to worries about addiction to the medication, 
intentional non-adherence due to worries about cost of the medication, intentional non-adherence 
due to lack of perceived need of the medication, and unintentional non-adherence. The MNPS 
yielded a single factor solution. Both scales demonstrated strong evidence of internal consistency 
reliability (all Cronbach’s α values and composite reliabilities were greater than 0.7), and 
convergent (all standardized factor loadings were greater than 0.5 and significant, and no 
evidence of cross-loadings was observed), discriminant (all chi-square difference values were 
above the critical value, and all average variance extracted values were at acceptable levels) and 
concurrent validity (relationships between the MNAS and PDC (unstandardized regression 
coefficient = -0.50 (p < 0.01)), and MNPS and days to discontinuation (unstandardized 
regression coefficient = -3.97 (p = 0.03)) were statistically significant and in the expected 
direction). Based on a ROC curve analysis of the MNAS, individuals who score more than ‘16’ 
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on the scale were considered non-adherent. Individuals who score more than ‘0’ on the MNPS 
were considered non-persistent. 
Conclusions 
The Medication Non-Adherence Scale (MNAS) and the Medication Non-Persistence Scale 
(MNPS) demonstrated good psychometric properties. They have been designed to help fill 
crucial gaps in relevant literature and health care practice. If used in a health care practice 
setting, these scales may help identify reasons behind such behavior, and aid in the development 
of tailored interventions to improve patient health.
44 
 
INTRODUCTION 
 
Medication non-adherence occurs when a patient misses, skips, delays, or takes more/less 
of the dose of the prescribed medication regimen.1–5 Medication non-persistence refers to 
stopping or discontinuation of the treatment regimen.4,6  Such behaviors are important issues in 
health care.1,2,7–10 Many studies conducted in chronic conditions such as diabetes mellitus, 
hypertension, hypercholesterolemia, and congestive heart failure have demonstrated the 
detrimental effects of medication non-adherence and non-persistence on hospitalizations, 
mortality, and resultant overall health care costs.8–10 Due to these reasons, effective and efficient 
measurement of medication non-adherence and medication non-persistence is necessary. 
There are numerous methods of measuring medication non-adherence in the scientific 
literature and healthcare practice. Broadly, these may be divided into ‘objective methods’ and 
‘subjective methods’.11 Objective methods include biological assays, pill counts, use of the 
electronic devices (e.g. Medication Events Monitoring System (MEMS)), pharmacy records and 
prescriptions claims, etc., while subjective methods include patient interviews, patient diaries 
and self-reported questionnaires. Despite the abundance of methods, no measure is universally 
agreed upon as a ‘gold standard'.5,11–18 As each of these instruments measure the construct 
differently, recent papers suggest that rather than anointing a measure as a gold standard, the 
choice of measurement should depend on the demands of the situation.14 In a health care practice 
setting, which is the focus of the current study, self-reported questionnaires may be the only
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pertinent tool to measure medication non-adherence. This argument is supported by the National 
Collaborating Centre for Primary Care and the Royal College of General Practitioners (London, 
UK), along with National Institute of Health and Clinical Excellence (NICE), and corroborated 
by Garfield and colleagues.14,19  
There are many self-reported instruments available for measuring medication non-
adherence – 1986 Morisky scale20, Medication Adherence Reasons Scale (MAR-Scale)21, 
Medication Adherence Rating Scale (MARS)22, Brief Medication Questionnaire (BMQ)23, 
Maastricht Utrecht Adherence in Hypertension (MUAH)24, Brief Adherence Rating Scale 
(BARS)25, Morisky Medication Adherence Scale26, etc. Currently, the most widely used self-
reported measure in a clinical setting is the 1986 Morisky scale.20 The primary reason for its 
popularity is its short length and its ability to be used as a disease non-specific instrument.27–31. 
Despite these advantages, it has often presented issues with psychometric properties.20,27,28,30–32 
The Morisky scale was updated in 2009 to improve upon its reliability, but this version has twice 
the number of items (as compared to the 1986 version), and has only been tested among 
hypertensive and diabetic patients.26,33–36 
Another shortcoming of many current instruments is that they often do not explicitly 
distinguish between the different reasons for medication non-adherence.14,37 Some scientific 
papers propose distinguishing the reasons for non-adherence based on intent, into intentional and 
unintentional non-adherence.14,38,39 Intentional medication non-adherence occurs when a patient 
makes a conscious decision to not comply with the medication regimen (e.g. stopping medication 
due to side- or adverse-effects, perceived lack of need, unaffordability, etc.). Unintentional 
medication non-adherence occurs when a patient simply forgets to take his/her medication(s). In 
their recent paper on the development of the Medication Adherence Reasons Scale (MAR-
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Scale), Unni and Farris stressed on the importance of further distinguishing between the different 
reasons for intentional non-adherence. They observed that non-adherence can occur due to four 
issues – practicality issues (e.g. not being able to open the container, pharmacy being out of 
medicine, etc.), lack of necessity belief issues (e.g. perceived need for medication, perceived 
effectiveness of medication, etc.), concern belief issues (e.g. possible side-effects or long-term 
effects), and forgetfulness issues. Irrespective of the depth of classification implemented, the 
necessity of distinguishing between the different reasons for medication non-adherence is 
unhindered because the interventions needed to counter each type are quite different.14,37 For 
example, reminder phone calls, SMSs, emails, etc. may work while intervening upon 
unintentional medication non-adherence or forgetfulness issues, while counseling may be 
necessary for dealing with intentional medication non-adherence or any of the other three issues 
mentioned in the MAR-Scale. 
Medication persistence is usually measured using prescription claims data, pharmacy 
refill records, pill counts, or clinical trials data.4,6,40,41 It is most often operationalized as the 
amount of time from initiation to discontinuation of the treatment regimen, or as a binary 
variable depicting whether the regimen was followed over the observation period or not.4,6,40,42–44 
Studies have indicated that behaviors such as stopping pharmacotherapy without the health care 
provider’s consent may result in adverse health and/or economic issues.9,10,40 Thus identification 
of patients who may have been non-persistent with their medications is important. Based on the 
recommendations by the National Collaborating Centre for Primary Care and the Royal College 
of General Practitioners (London, UK), and National Institute of Health and Clinical Excellence 
(NICE), this may be achieved by the use of self-reported measures.19 But currently, health care 
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research and practice lacks multi-item self-reported measures of medication non-persistence. 
Such measures can also aid in the identification of reasons for non-persistence. 
In order to address these gaps in current scientific literature, this paper proposes the 
development of the Medication Non-Adherence Scale (MNAS) and the Medication Non-
Persistence Scale (MNPS). As discussed above, the MNPS is the first multi-item self-reported 
measure of medication non-persistence. Thus, its development is important to health care 
research and practice. But there are numerous self-reported measures of medication non-
adherence in the scientific literature. The MNAS has been designed to offer five beneficial 
properties. First, it is designed to be disease non-specific. This will enable implementation of the 
MNAS in a variety of therapeutic areas. Second, the MNAS is grounded in theory. Conventional 
health behavior theories such as the social learning theory/social cognitive theory, theory of 
reasoned action/theory of planned behavior, health behavior model, transtheoretical model, etc. 
offer explanations for intentional medication non-adherence.45–49 The model of accident 
causation promises to explain the intentional and unintentional aspects of this medication-taking 
behavior, and has been recommended as a conceptual framework for aiding in the 
operationalization of this distinction.14,38,39,50,51 According to this model, unintentional 
medication non-adherence can be defined as a ‘slip’ (an outcome of lack of attention) or a ‘lapse’ 
(an outcome of forgetfulness), while intentional medication non-adherence can be defined as a 
‘mistake’ (intentional implementation of an inappropriate action in a given scenario) or 
‘violation’ (a deliberate implementation of an normatively unsafe action).38 The MNAS is based 
on this model, and the suggestions offered by Unni and Farris21,37 in their development of the 
Medication Adherence Reasons Scale (MAR-Scale). This ability to distinguish between the 
different reasons for medication non-adherence is the third advantage offered by the MNAS. 
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Fourth, it is developed using proportion of days covered (PDC) as the criterion measure. This 
objective measure is recommended for the measurement of medication adherence for use in the 
assessment of pharmacy quality by the Pharmacy Quality Alliance (PQA) and the Centers for 
Medicare and Medicaid Services.52,53 Thus, the MNAS will offer self-reported estimates of the 
patients’ PDCs to health care providers who choose to use it. Finally, the ultimate goal of this 
scale development exercise is to offer practitioners a relatively short, simple, and readily 
interpretable instrument to help assess medication non-adherence in a practice setting. Although 
other scales offer many of the properties discussed above, to the best of our knowledge, no scale 
offers all five. The MNAS has the potential of helping health care practitioners and researchers 
improve their assessment of medication non-adherence. 
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METHODOLOGY 
 
Description of the Proposed Instruments 
The Medication Non-Adherence Scale (MNAS) has been designed as a disease non-
specific instrument with the ability to distinguish between the different reasons for medication 
non-adherence. The instrument is based on Barber’s adaptation of the model of accident 
causation proposed by Reason38,39,50,51, and the insight offered by Unni and Farris21,37 in the 
development of the Medication Adherence Reasons Scale (MAR-Scale). The items were 
developed based on the 1986 Morisky scale20, the Medication Adherence Scale (MAS)54, the 
Morisky Medication Adherence Scale26, the Medication Adherence Rating Scale (MARS)22, the 
Reported Adherence to Medication (RAM) scale55, and the guidance offered by Barber38,39, 
Garfield et al.14, and Unni and Farris21,37. All items were scored from ‘1’ through ‘5’on a five 
point Likert-scale with options ‘Never’, ‘Rarely’, ‘Sometimes’, ‘Often’, and ‘Always’. The final 
scale items can be viewed in the appendix. 
Unlike the MNAS, which is theory-based, development of the MNPS was an exploratory 
endeavor. The MNPS items can be viewed in the appendix. The items were worded such that a 
binary (yes or no) response is obtained. Each pro-non-persistence response was coded as ‘1’, 
while each pro-persistence response will be coded as ‘0’. These scores were summed to form one 
patient specific score for medication non-persistence. A summated score of ‘0’ (zero)
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represented perfect medication persistence, while anything higher indicated some form of non-
persistence. 
 
Pretests 
Prior to conducting the study, the MNAS and the MNPS underwent two rounds of 
qualitative pretest evaluations (Pretest 1 and 2), and one round of quantitative pretest evaluation 
(Pretest 3). Pretest 1 was conducted among eight faculty members at a university in the 
Southeastern region of the United States with experience in self-reported scale development. The 
purpose of this pretest was “subjective validation” (i.e. face and content validity) of the scales.56 
It was conducted by distributing the then current versions of the MNAS and MNPS to the sample 
frame via email, and receiving feedback by the same medium. This feedback was evaluated, and 
appropriate suggestions were incorporated into the wording of the items. Pretest 2 was conducted 
among six staff members at the same university, who were users of prescription medications for 
chronic conditions. Its purpose was to assess sources of response error in the proposed 
instruments by conducting six cognitive interviews.57–60 Based on the arguments presented by 
Beatty and Willis, a combination of ‘think-aloud’ and ‘probing’ techniques were used to help 
improve the scales.57 Patients were recruited via email. Their responses were recorded using a 
digital voice recorder. They were offered a $10 gift card to an online store in exchange for their 
participation. The voice recordings were transcribed, and important points were marked for 
consideration. The MNAS was modified by adding two items pertaining to unintentional non-
adherence, and one pertaining to intentional non-adherence. The MNPS was left unaltered. 
Pretest 3 was conducted to empirically assess internal consistency reliability (Cronbach’s 
alpha and composite reliability), and convergent and discriminant validity of the MNAS and 
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MNPS, and their potential to invoke a socially desirable response.61–65 To achieve these aims, a 
cross-sectional, observational study was conducted by administering the scales as an internet-
based survey to a convenience sample of full-time students, faculty, and staff at a university in 
the Southeastern region of the United States, who take at least one prescription medication 
indicated for a chronic condition. In order to help increase sample size, the patients were entered 
into a drawing to win one of ten $25 gift cards to an online store. This method yielded 214 usable 
responses. The instrument administered contained six sections – screener, the MNAS items, the 
MNPS items, socially desirable response bias assessment questions65, demographic 
characteristics, and patient comments. Patients were screened based on the number of 
medications for chronic conditions prescribed; only patients that consumed at least one such 
medication were included in the study. Data collected were analyzed in SAS 9.3 (SAS Institute 
Inc., Cary, NC) and Mplus 7.2 (Muthén & Muthén, Los Angeles, CA, USA). For calculating 
internal consistency reliability, Cronbach’s alphas were calculated using the ‘CORR’ procedure 
in SAS with the ‘ALPHA’ option*, and composite reliability was calculated using the method 
described by Fornell and Larcker.61,62 Further, convergent and discriminant validity of the 
measures was tested using the procedures outlined by Anderson and Gerbing, and Kline.63,64 
Details about these procedures can be found in the analysis section of the study below. These 
analyses resulted in a two factor solution for the MNAS – intentional non-adherence and 
unintentional non-adherence – and a one factor solution for the MNPS. Based on these results 
and the statements mentioned in the comments section of the survey, two items were added to 
the MNAS – “I missed a dose of my medication because I did not get it refilled before I ran out” 
and “I missed a dose of my medication because I forgot to take it with me”. Also, the need-based 
items in the MNAS were reworded to exclude the “at that time” portion of the statements. The 
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MNPS was modified by adding an item – “I stopped taking my medication because the 
medication did not work”. Potential for socially desirable response bias was tested using the 
method described by Steenkamp, de Jong, and Baumgartner.65 No statistical evidence of such 
bias was observed. 
 
Study 
Following changes to the MNAS and MNPS based on the results of the pretests, the 
scales were administered to a sample of patients currently consuming medications for 
hypertension, diabetes, and dyslipidemia.† 
Study objectives and study design. This study had the following objectives: 
 To calculate internal consistency reliability of the MNAS and MNPS (using Cronbach’s 
alpha, and composite reliability as instructed by Fornell and Larcker)61,62 
 To study convergent and discriminant validity of the MNAS and MNPS using the methods 
outlined by Anderson and Gerbing, Kline, and Fornell and Larcker62–64 
 To study the concurrent validity of the MNAS and MNPS using measures calculated using 
prescription fill data as their respective objective measures (an adaptation of the NCQA 
PDC measure‡ and time to discontinuation, respectively)4,40 
 To calculate sensitivity and specificity of the MNAS and MNPS by classifying their scores 
into meaningful categories using receiver-operating characteristic (ROC) curves66,67  
A retrospective observational study was conducted to meet these objectives. Data for the 
MNAS and MNPS were collected from patrons of three independent community pharmacies in 
the Southeastern United States. Retrospective prescription fill data for these patrons were 
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obtained from the pharmacies under consideration, and the self-reported data were linked with it 
to meet the aforementioned objectives. 
Sample design and data collection. The target population of the study was prescription 
medication users who have been directed by their health care provider to consume at least one 
prescription medication indicated for a chronic condition. After finalizing Data Use Agreements 
(DUAs) with three independent community pharmacies in the Southeastern region of the United 
States, prescription fill data were obtained for a 12-month period prior to the date of data 
request§. These data were used to identify the sample frame. In these data, patients were only 
referenced using a unique patient identifier (PTID). Patients, 18 years and older, were selected 
based on whether they filled at least one prescription for a medication in one of the seven 
therapeutic categories of interest specified by the National Committee for Quality Assurance 
(NCQA)44, starting at least 6-months prior to the end of the data. These therapeutic categories 
included beta-blockers (BBs), angiotensin-converting enzyme (ACE) inhibitors or angiotensin-
receptor blockers (ARBs), calcium channel blockers (CCBs), biguanides, sulfonylureas, 
thiazolidinediones, and statins.44 Only PTIDs that had prescription fills for at least one of the 
seven categories, and starting at least 6 months before the end of the data, with the last fill ending 
at least 90 days after the first started, were included in the sample frame. This resulted in a 
sample frame with 4,554 patients. The PTIDs in these data were then linked to patient names and 
addresses by an independent data manager. The involvement of the independent data manager 
ensured that the researchers did not have access to any patient identifiers in accordance with the 
Health Insurance Portability and Accountability Act (HIPAA).68 
 Survey instrument packets were then created for each patient in the sample frame. These 
packets included a cover letter from the patronized pharmacy informing the patients about the 
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study and the survey instrument (containing a screener for whether they used the pharmacy we 
obtained their data from for most of their medications, the MNAS, MNPS, and demographic 
questions) printed on a business reply mailer, and were enclosed in an envelope with the 
appropriate name and address printed on a label on top. Each survey instrument contained a 
unique mailing identifier (MID) that was patient specific, and linked to the PTID. A matching 
MID was also printed on the address label to ensure that the survey instrument reached the 
correct patient. The MID was linked to the PTID by the researchers, and the PTID was linked to 
the patients’ names and addresses by the independent data manager; neither had access to the 
other’s crosswalk files. This method of using a second-level ID (rather than using the PTID for 
mailing) was implemented to further ensure that patients’ identities were not exposed. The 
packets were then mailed via the United States Postal Service. Recipients were expected to 
complete the instrument and mail it back using the business reply mailer.  
Data management. Data collected using the survey instrument were manually entered into a 
Microsoft Excel file. These data were then cleaned to eliminate patients who did not responded 
to items on the MNAS and MNPS (or provided invalid responses) and did not use the pharmacy 
we obtained their data from for most of their medications. The dataset was then converted into a 
SAS dataset and merged with the prescription fill data using the MID and PTID. This resulted in 
a single patient-fill level file. This file was further aggregated into a patient-therapeutic category 
level file. Each patient was assigned their own observation period based on the date of survey 
return postmark. For calculating the adaptation of the NCQA PDC measure, the observation 
period ranged from 7 months prior to the date of survey return postmark to 1 month after, while 
the measurement period ranged from the start of the first prescription fill 6 months prior to the 
date of survey return postmark to the end of the last prescription fill on or before that date (i.e. 
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date of survey return postmark). A 6-month measurement period was chosen based on the recall 
period for the MNAS. A 30-day period prior to the start of the measurement period was observed 
(pre-measurement period) to account for potential prescription fill overlaps from that period, and 
a 30-day period was observed after the end of the last fill in the measurement period (post-
measurement period) to distinguish between potential discontinuation (i.e. absence of a 
prescription fill/refill for the therapeutic category under consideration in the post-measurement 
period) and potential non-adherence (i.e. presence of a prescription fill/refill for the therapeutic 
category under consideration in the post-measurement period). If potential non-adherence was 
observed, the measurement period was altered to end on the date of survey return postmark (even 
if the “last prescription fill” ended before this date). Data within the measurement period were 
used to calculate PDCs using the following formula42,69–71: 
PDC = 
Number of days the patient is covered by the drug in the measurement period
Number of days in the measurement period
 
A days to discontinuation score was also calculated for each therapeutic category consumed. For 
this calculation, the observation period ranged from 13 months prior to the date of survey return 
postmark to 1 month after. The measurement period, in this case, ranged from the start of the 
first prescription fill 12 months prior to the date of survey return postmark to the end of the last 
prescription fill on or before that date (i.e. date of survey return postmark). A 12-month 
measurement period was chosen in concordance with the MNPS recall period. The days to 
discontinuation score was calculated by adding the days until a gap in medication therapy of 30 
days or more was experienced by the patient.42–44 The therapeutic category-specific PDCs and 
days to discontinuation scores thus obtained were then averaged to calculate patient-specific 
mean PDCs and days to discontinuation scores.43 Further, the patient-specific mean days to 
discontinuation score was standardized by dividing by number of days in the patient’s 
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measurement period and multiplying by 100. This was done to make the measure comparable 
across patients, as is in the case of PDCs. Thus the standardized patient-specific mean days to 
discontinuation score represented the number of days to discontinuation in a 100-day 
measurement period. Based on the NCQA guidelines for calculating PDCs, a minimum drug 
coverage of 90 days for MNAS validation, and 150 days for MNPS validation, was deemed 
appropriate.44  
Data analysis. All analyses were conducted in SAS 9.4 and Mplus 7.3. Two confirmatory factor 
analyses (CFAs) were conducted. One CFA was conducted for MNAS in SAS 9.4 with 
maximum likelihood estimation, and the other for MNPS in Mplus 7.3 with robust weighted least 
square estimation (WLSMV – weighted least squares with mean and variance adjustment).** 
Final factor structures were established for the two scales using the results of additional 
exploratory factor analyses conducted on the Pretest 3 data as a guideline. The first aim of this 
study was to calculate internal consistency reliability. This was done using two methods. First, 
Cronbach’s alphas were calculated for the sub-scales of MNAS, and MNPS using the CORR 
procedure in SAS 9.4 with the ALPHA option. Second, composite reliabilities (CR) were 
calculated for these scales using the method described by Fornell and Larcker.62 This involves 
using the values obtained in the confirmatory factor analyses described above in the formula 
below: 
CR = 
Sum of standardized factor loadings squared
(Sum of standardized factor loadings squared + Sum of standardized error terms)
 
 The second aim of this study was to test the convergent and discriminant validity of the 
MNAS and the MNPS. The results of the confirmatory factor analyses conducted for objective 1 
were used to achieve this objective as well. To check for convergent validity, standardized factor 
loadings were observed to identify items with values below 0.5. Statistically nonsignificant 
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standardized factor loadings were then identified.63 Further, modification indices (Lagrange 
Multiplier (LM) statistics) were inspected for evidence of potential cross-loadings (i.e., large 
values of LM statistics).64 
Discriminant validity for the MNAS was assessed using the approach suggested by 
Anderson and Gerbing.63 In this technique, the completely unconstrained model (in this case, the 
MNAS model on which the CFA was originally run) is referred to as the base model. The chi-
square estimate for this model is noted. Then, covariance between each pair of factors is 
iteratively fixed at one, one at a time. At each iteration, the model is run, and the chi-square 
estimate is noted. If this difference between each such estimate and that of the base model is 
found to be greater than 3.84 (at α = 0.05), we can say that there is evidence of discriminant 
validity between the corresponding pair of factors. In addition to these calculations, average 
variance extracted (AVE) was also calculated for the MNAS sub-scales, and the MNPS.62 The 
formula for calculating AVE has been given below: 
AVE = 
Sum of squared standardized factor loadings
(Sum of squared standardized factor loadings + Sum of standardized error terms)
 
If an AVE value is observed to be greater than or equal to 0.5, or if it is lesser than 0.5 but is 
greater than its squared correlation with the other sub-scales/scale, we can say that there is 
evidence to suggest discriminant validity.62 
 The scores on items under each sub-scale were then summed to denote the score on that 
sub-scale. In order to study the concurrent validity of the MNAS, two multiple linear regressions 
were conducted. The first model contained the summated forms of the MNAS sub-scales as 
independent variables (i.e. each sub-scale as a separate IV), important demographic variables as 
covariates††, and the patient-specific mean PDC measure as the dependent variable. The second 
model replaced the summated sub-scale scores in the prior model with a summated overall 
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MNAS score (i.e. only one IV). The SAS 9.4 GLM procedure was used for these analyses (using 
a significance level of 0.05). 
Using a procedure similar to that outlined above, concurrently validity of the MNPS was 
studied against the standardized patient-specific days to discontinuation measure of persistence. 
A multiple linear regression was conducted using the summated MNPS score as the independent 
variable, important demographic variables as covariates††, and the standardized patient-specific 
days to discontinuation score as the dependent variable. This was done using PROC GLM in 
SAS 9.4 (using a significance level of 0.05). 
The last objective of this study was to classify the scores on the MNAS and the MNPS 
into meaningful categories. This was done to allow calculation of sensitivity and specificity of 
the scales, and more importantly, enable better interpretability in a health care practice setting. 
To do this, two receiver-operating characteristic (ROC) curves were plot, one for the MNAS, and 
another for the MNPS. This was done using the LOGISTIC procedure in SAS 9.4 with the 
PLOTS = ROC option. First, the patient-specific mean PDC and the patient-specific days to 
discontinuation (i.e. non-persistence) variables were converted into their categorical forms. In the 
case of PDC a 95% adherence criteria was used; individuals with a PDC of 95% or more were 
classified as ‘adherent’, while those with a PDC of less than 95% as ‘non-adherent’.‡‡ For the 
standardized days to discontinuation measure, individuals who had not discontinued any of their 
medications in the measurement period (i.e. when value on this measure was 100) were classified 
as ‘persistent’, while all others as ‘non-persistent’. The ROC curve for MNAS were plot using 
the overall average MNAS score and the categorical patient-specific PDC variable. Similarly, the 
summated score on the MNPS, and the dichotomous standardized patient-specific days to 
discontinuation score were used to calculate the persistence ROC curve. These curves, and the 
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dataset generated from the LOGISTIC procedure (using the OUTROC option) were used to 
determine optimum cut-off points for the proposed scales. 
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RESULTS 
 
Sample Description 
After 40 days in the field, 831 completed responses were obtained, while 611 packets 
were returned by the USPS due to address issues. Thus, a response rate of 21.08% was observed 
(831 ÷ (4,554-611)). Following this, patients who either provided invalid responses to the MNAS 
or MNPS items, or did not use one of the three pharmacies under consideration for most of their 
medications for chronic conditions were eliminated. This resulted in the elimination of 124 
patients. Furthermore, as mentioned in the prior section, different minimum drug coverage 
criteria were applied for MNAS (90 days) and MNPS (180 days) validation. Due to this, two 
separate patient-level files were created – the MNAS analysis file containing 685 patients, and 
the MNPS analysis file containing 675. 
Table 1 provides information about the MNAS and MNPS sample characteristics. 
Considering the fact that patients were required to consume at least one medication for a chronic 
condition, and were administered a paper instrument (rather than online), the sample primarily 
comprised of middle-aged to old individuals. About 63% of the MNAS sample and about 60% of 
the MNPS sample was greater than 60 years of age. Considering that the number of medications 
prescribed usually increase with age, such an age distribution was deemed appropriate for the 
purposes of this study. The sample was also primarily white (87.3% for MNAS, 87.7% for 
MNPS), female (56.5% for MNAS, 56.9% for MNPS), and married (64.8% for MNAS, 65.3%
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for MNPS). About 26% reported to having at least a college degree in either sample. Most 
patients (65.8% in both samples) were prescribed 3 to 8 medications for chronic conditions, with 
at least one of them being for diabetes, hypertension or dyslipidemia. Around 60% of either 
sample were either insured by Medicare, private insurance, or both, and most reported their 
health status as being ‘good’ (41.9% for MNAS, 39.9% for MNPS). 
 
Confirmatory Factor Analysis, Internal Consistency Reliability, and Convergent and 
Discriminant Validity 
Results of the confirmatory factor analysis for the MNAS can be viewed in Table 2.§§ 
The analysis yielded a five factor solution – Intentional non-adherence due to worries about side-
effects (MNAS-I-Side-effects – 4 items), intentional non-adherence due to worries about 
addiction to the medication (MNAS-I-Addiction – 2 items), intentional non-adherence due to 
worries about cost of the medication (MNAS-I-Cost – 2 items), intentional non-adherence due to 
lack of perceived need of the medication (MNAS-I-Perceived need – 4 items), and unintentional 
non-adherence (MNAS-U – 4 items). Confirmatory factor analysis results for the MNPS can be 
viewed in Table 3. This analysis yielded a single factor solution. The MNAS and MNPS items 
can be viewed in the appendix. Cronbach’s α and composite reliability values for the MNAS 
sub-scales and MNPS can be viewed in Table 4. These values were greater than the 
recommended minimum of 0.7 on both measures.61,62,72 Based on these results, we can say that 
we have sufficient evidence of internal consistency reliability for all sub-scales of MNAS and the 
MNPS.  
Next, standardized factor loadings obtained in the CFA were observed to identify 
statistical nonsignificance and value below 0.5 (see Table 2 and 3). No such instance was 
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observed. After accounting for correlated errors in the MNAS model, all Lagrange Multiplier 
statistics were within limits, and no evidence of potential cross-loadings was observed. These 
findings indicated sufficient evidence of convergent validity.63,64 
 The method suggested by Anderson and Gerbing63 and average variance extracted 
(AVE)62 were used to assess discriminant validity in the MNAS, while only the latter was used 
for the MNPS. Using the prior approach for the MNAS, all chi-square differences observed were 
greater than 3.84 (critical value at α = 0.05). The AVE value for all summated MNAS sub-scales 
scores, except unintentional non-adherence, was greater than 0.5. In the case of MNAS-U, AVE 
was observed to be 0.49. However, as this value was higher than the squared correlations of 
MNAS-U with the other sub-scales, all the MNAS sub-scales were concluded to demonstrate 
discriminant validity. AVE for the MNPS was computed to be 0.62, thus offering evidence for 
discriminant validity. The AVE values, correlation coefficients, and squared correlation 
coefficients can be viewed in Table 4. 
 
Concurrent Validity 
The MNAS sub-scale item scores were first summed, and then subjected to concurrent 
criterion validation using the patient-specific mean PDC. Based on the results of a set of 
univariable analyses conducted by regressing the patient-specific mean PDC on each measured 
demographic variable, the variable ‘age’ (measured in years) was included in the analysis as a 
covariate. First, the patient-specific mean PDC was regressed on the five MNAS sub-scale 
scores. This analysis indicated that the factor concerned with intentional non-adherence due to 
worries about medication costs (MNAS-I-Costs) was the only sub-scale that was statistically 
significantly associated with the patient-specific mean PDC (unstandardized regression 
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coefficient = -1.94 (p < 0.01)). Also, the relationship between patient-specific mean PDC and the 
factor concerned with intentional non-adherence due to a perceived lack of need of medication 
(MNAS-I-Perceived need) was marginally significant (unstandardized regression coefficient = -
0.71 (p = 0.08)).*** A second linear regression model was run to assess the relationship between 
the summated overall MNAS score and patient-specific mean PDC. Result of this analysis 
indicated that there was a statistically significant relationship between the overall MNAS score 
and the patient-specific mean PDC (unstandardized regression coefficient = -0.50 (p < 0.01)). 
These results can be viewed in Table 5. Thus, based on this result, we can say that there is 
evidence to suggest that the MNAS has concurrent validity with the patient-specific mean PDC. 
To assess concurrent validity of the MNPS, the scores on the items were summed to 
calculate one patient-specific MNPS score. Similar to the concurrently validation of the MNAS, 
a model building approach was used and the variable ‘age’ was included in the criterion 
validation analysis with the standardized patient-specific mean days to discontinuation score. 
The relationship between the MNPS score and the objective measure was not found to be 
statistically significant (unstandardized regression coefficient = -0.84 (p = 0.21)). As the 
development of the MNPS was an exploratory exercise, scoring on the MNPS was modified to 
enable better prediction of the objective measure; the summated MNPS variable was modified to 
a dichotomous variable with a value of ‘1’ for patients with a score of ‘1’ or more on the original 
MNPS (i.e. those who answered ‘Yes’ on at least one of the 9 items), and a value of ‘0’ for 
patients with a score of ‘0’ (i.e. those who did not answer ‘Yes’ on any item). After this 
modification, the MNPS was seen to demonstrate a statistically significant relationship with the 
standardized patient-specific mean days to discontinuation score (unstandardized regression 
coefficient = -3.97 (p = 0.03)). These results can be viewed in Table 6. Based on this result, we 
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can say that there is evidence to suggest that the MNPS has concurrent validity with the 
standardized patient-specific mean days to discontinuation score. 
 
ROC Curve Analysis, Sensitivity, Specificity and Meaningful Categorization of Scale 
Scores 
The ROC curve for MNAS presented a c statistic of 0.63. The dataset generated with the 
OUTROC option provided a range of predicted probabilities, sensitivity, and 1-specificity 
values. Using Youden’s J73 as a guideline, a cut-off point of 16.60 was obtained.††† At this point, 
the scale had a sensitivity of 0.74 and specificity of 0.45. To improve implementation of the 
MNAS in estimating PDC at a health care practice setting, because a score beyond 16 on the 
MNAS indicated that the patient selected a response other than ‘Never’ on at least one item, a 
cut-off point of 16 was deemed appropriate (a score beyond 16 indicates non-adherence), and 
thus finalized. At this point, the sensitivity was 0.81 and specificity was 0.30. 
For the MNPS, the c statistic was observed to be 0.53 and the relationship between the 
original form of the scale and dichotomous standardized patient-specific days to discontinuation 
score was not statistically significant. Thus no further attempt was made to arrive at a cut-off 
point using this method. Rather, the dichotomous MNPS variable created in the concurrent 
validation process was considered to be the best representation of the scale for use in a health 
care practice setting, i.e. a score beyond 0 on the MNPS indicated non-persistence (as measured 
using the standardized patient-specific days to discontinuation score). However, this cut-off point 
yielded a sensitivity of only 0.24. The specificity value at this point was 0.82. 
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DISCUSSION 
 
Numerous papers have demonstrated the ill-effects of non-adherence.8–10 Yet based on 
our literature review, no self-reported adherence measure in health care practice has presented 
with good psychometric properties, is designed to be disease non-specific, and can help 
distinguish between the different reasons for non-adherence. This paper presents evidence for the 
Medication Non-Adherence Scale (MNAS) bearing those properties. Also, the ability of the 
MNAS in offering a self-reported estimate of the proportion of days covered (PDC) measure40 is 
presented here. 
There is also evidence to suggest that non-persistence results in a similar, if not worse, 
health and economic impact as non-adherence.9,10 But the construct lacks a method of 
measurement that can offer health care practitioners an immediate estimate of their patients’ 
relevant behaviors, and reasons for the same. This paper develops and presents evidence for one 
such measure – the Medication Non-Persistence Scale (MNPS). 
 
Interpretation of Results and Recommendations for Use in a Practice Setting 
 A CFA of the MNAS yielded a five factor solution with four factors (worries about side-
effects, worries about addiction to the medication, worries about cost of the medication, and lack 
of perceived need of the medication) concerned with intentional non-adherence, and one with 
unintentional non-adherence. The scale demonstrated good internal consistency reliability and
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validity (convergent, discriminant, and concurrent). The concurrent validity analysis indicated 
that on average for every one unit increase in the overall MNAS score (higher score indicates a 
higher level of medication non-adherence), the adapted 6-month PDC measure dropped by 0.5 
percentage points. Also, the ROC curve analysis indicated that a score of greater than 16 on the 
MNPS indicated a PDC of less than 95%. Thus if a patient presents with such a score on the 
MNAS, the sub-scales must be assess to identify reason(s) for non-adherence. This assessment 
can enable implementation of an appropriate medication adherence intervention strategy. 
 Results of the CFA conducted on the MNPS items indicated a single factor structure. 
This scale demonstrated good internal consistency reliability and validity (convergent, 
discriminant, and concurrent). Based on the analysis conducted during validation, a score of 
greater than ‘0’ (zero) was deemed to indicate non-persistence, although this cut-off point 
presented with a low sensitivity value (0.24). Furthermore, individuals who indicated non-
persistence on the MNPS were seen to stop medication consumption on average about four days 
before those who did not, in a 100-day period; i.e. on average about 15 days earlier in a one year 
period. If a patient presents with a score higher than ‘0’ on the MNPS, their responses should be 
observed to identify the reason(s) for non-persistence, and an appropriate intervention strategy 
should be implemented. 
 
Limitations of the Scales and Directions for the Future 
  Although this paper demonstrates strong evidence for reliability, validity, and 
applicability of the MNAS and MNPS, a few issues must be acknowledged before using these 
scales for research or in health care practice.  The pretests and the study were conducted in three 
independent community pharmacies in the Southeastern region of the US, thus the authors 
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cannot make any claim about generalizability beyond this geographic area. Future studies need to 
test these scales in different geographic and socio-demographic samples to improve their external 
validity. 
 The MNAS and MNPS presented good statistical predictability of their objective 
counterparts, but the amount of variation explained in their respective criterion variables was 
observed to be quite low – 5.87% for MNAS and 1.32% for MNPS. Users of these scales must 
be cognizant of this shortcoming. The effect such an r2 is seen in the poor specificity value of the 
MNAS (0.45). Such numbers potentially indicate an incomplete estimation of the objective 
measure. Although a thorough attempt was made by employing multiple rounds of qualitative 
and quantitative pretesting, future research should try and ensure that all aspects of the PDC 
construct are estimated by including additional factors for other reasons for non-adherence and 
non-persistence. One aspect of non-adherence that could be considered by future researchers is 
‘over-dosing’. The authors attempted to include items purporting to measure over-dosing in the 
MNAS, but they were removed due to model fit and cross-loading issues. An alternate 
explanation for this occurrence is the presence of socially desirable response bias. Although no 
statistical evidence was found for this bias in the pretests, it may have affected prediction in the 
study.‡‡‡ This hypothesis requires confirmation. 
 The work presented here does not study the comparative effectiveness of contemporary 
adherence scales in predicting PDC. Thus no claims can be made about the comparative 
performance of the MNAS. Future studies should assess the ability of other contemporary 
adherence scales like the 1986 Morisky scale20, Medication Adherence Reasons Scale21, etc. in 
predicting PDC, and compare results obtained using the MNAS. 
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 Ideally, to develop better adherence interventions in a health care practice setting, having 
an estimate of the propensity for non-adherence in the future is more beneficial than an estimate 
of how a patient has behaved in the past. The Adherence Estimator® (AE)74–76 is an example of a 
scale that has been developed for this purpose. The MNAS has not been tested for this ability. 
Future studies should assess the comparative predictive ability of the MNAS and the AE. 
 
Conclusion 
 This paper outlined the development of two self-reported instruments that can be used to 
assess medication adherence and medication persistence in health care practice and research. The 
Medication Non-Adherence Scale (MNAS) was shown to distinguish between different reasons 
for non-adherence, and estimate concurrent and future medication non-adherence. It was tested 
in patients consuming medications indicated for diabetes, hypertension, and/or dyslipidemia, in a 
disease non-specific context. As indicated by a review of the literature, the Medication Non-
Persistence Scale (MNPS) is the first multi-item self-reported measure of medication persistence. 
It was also tested in a similar disease non-specific context. Both scales were developed to enable 
relatively easy interpretation in a clinical setting, and allow health care practitioners to 
understand the reasons driving their patients’ medication taking behavior.  
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APPENDIX A 
 Table 1 
Description of MNAS and MNPS sample demographic characteristics 
Demographic Characteristics 
MNAS MNPS 
# % # % 
Age 
<= 45 43 6.3% 42 6.2% 
46 – 60 201 29.3% 200 29.6% 
61 – 70 196 28.6% 194 28.7% 
71 – 80 164 23.9% 161 23.9% 
> 80 81 11.8% 78 11.6% 
Gender 
Male 228 33.3% 226 33.5% 
Female 387 56.5% 384 56.9% 
Missing 70 10.2% 65 9.6% 
Race 
White 598 87.3% 592 87.7% 
Other races 84 12.3% 81 12.0% 
Missing 3 0.4% 2 0.3% 
Education 
Up to high school graduate 277 40.4% 275 40.7% 
Some college (no degree), trade or technical school, or associate degree 224 32.7% 222 32.9% 
Bachelors, professional, or graduate degree 178 26.0% 174 25.8% 
Missing 6 0.9% 4 0.6% 
Marital Status 
Married 444 64.8% 441 65.3% 
Currently not married 240 35.0% 234 34.7% 
Missing 1 0.1% 0 0.0% 
8
6
 
 Income 
Under $20,000 167 24.4% 164 24.3% 
$20,000 to $39,999.99 166 24.2% 166 24.6% 
$40,000 to $59,999.99 95 13.9% 94 13.9% 
$60,000 to $79,999.99 64 9.3% 63 9.3% 
$80,000 or more 145 21.2% 143 21.2% 
Missing 48 7.0% 45 6.7% 
No. of Medications 
1 – 2 83 12.1% 83 12.3% 
3 – 4 170 24.8% 166 24.6% 
5 – 6 166 24.2% 164 24.3% 
7 – 8 115 16.8% 114 16.9% 
9 – 10 56 8.2% 55 8.1% 
> 10 72 10.5% 71 10.5% 
Missing 23 3.4% 22 3.3% 
Health Insurance 
Medicare 402 58.7% 393 58.2% 
Medicaid 74 10.8% 73 10.8% 
Private 435 63.5% 430 63.7% 
Uninsured 39 5.7% 39 5.8% 
Tricare 9 1.3% 8 1.2% 
Don’t know 7 1.0% 7 1.0% 
Missing 4 0.6% 3 0.4% 
Health Status 
Excellent 20 3.1% 20 3.0% 
Very Good 171 26.3% 169 25.0% 
8
7
 
 Good 272 41.9% 269 39.9% 
Fair 180 27.7% 177 26.2% 
Poor 4 0.6% 39 5.8% 
Missing 2 0.3% 1 0.1% 
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APPENDIX B
 Table 2 
Confirmatory factor analysis results for the Medication Non-Adherence Scale 
Constructs and Itemsa 
Standardized 
Loadingb 
MNAS – Intentional – Side-effects 
I skipped a dose of my medication because I was worried about its side effects. 0.72 
I skipped a dose of my medication because I was having side effects. 0.83 
I took a smaller amount of my medication because I was worried about its side effects. 0.86 
I took a smaller amount of my medication because I was having side effects. 0.79 
MNAS – Intentional – Addiction 
I skipped a dose of my medication because I was worried about getting addicted to it. 0.94 
I took a smaller amount of my medication because I was worried about getting addicted to it. 0.89 
MNAS – Intentional – Cost 
I skipped a dose of my medication because I was worried about costs. 0.91 
I took a smaller amount of my medication because I was worried about costs. 0.81 
MNAS – Intentional – Perceived need 
I skipped a dose of my medication because I was feeling better. 0.77 
I skipped a dose of my medication because I did not need it. 0.70 
I took a smaller amount of my medication because I was feeling better. 0.80 
I took a smaller amount of my medication because I did not need it. 
0.72 
9
0
 
 Constructs and Itemsa 
Standardized 
Loadingb 
 
MNAS – Unintentional 
I forgot to take a dose of my medication. 0.64 
I missed a dose of my medication by mistake. 0.61 
I missed a dose of my medication because I did not get it refilled before I ran out. 0.78 
I missed a dose of my medication because I forgot to take it with me. 0.77 
Overall Fit: 
χ2 (and df)  273.47 (df = 87) 
CFI 0.98 
RMSEA (90% CI) 0.06 (0.05, 0.06) 
a The model accounted for high error correlations (Lagrange Multiplier statistics). 
b All standardized factor loadings were statistically significant at α = 0.001. 
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APPENDIX C
 Table 3 
Confirmatory factor analysis results for the Medication Non-Persistence Scale 
Constructs and Items 
Standardized 
Loadingd 
I stopped taking my medication because I was worried about its side effects. 0.96 
I stopped taking my medication because I was having side effects. 0.90 
I stopped taking my medication because I was feeling better. 0.90 
I stopped taking my medication because I was worried about getting addicted to it. 0.74 
I stopped taking my medication because I did not need it anymore. 0.90 
I stopped taking my medication because I did not want to take it. 0.76 
I stopped taking my medication because it was inconvenient. 0.59 
I stopped taking my medication because I was worried about costs. 0.58 
I stopped taking my medication because the medication did not work. 0.68 
Overall Fit: 
χ2 (and df) 95.75 (df = 27) 
CFI 0.96 
RMSEA (90% CI) 0.06 (0.05, 0.07) 
d All standardized factor loadings were statistically significant at α = 0.001. 
9
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APPENDIX D 
 Table 4 
Sub-scale means, standard deviations, Cronbach’s α, correlations, composite reliability, and average variance extracted 
  Mean 
Std. 
Dev. 
Cronbach’s 
α 
X1 X2 X3 X4 X5 X6 
X1 MNAS-I-Side Effects 1.17 0.42 0.87 0.88/0.64 0.26 0.12 0.16 0.08 0.22 
X2 MNAS-I-Addiction 1.11 0.40 0.91 0.51 0.91/0.84 0.12 0.21 0.08 0.19 
X3 MNAS-I-Cost 1.25 0.60 0.85 0.35 0.34 0.85/0.74 0.12 0.20 0.12 
X4 MNAS-I-Perceived Need 1.17 0.41 0.83 0.4 0.46 0.34 0.84/0.56 0.16 0.31 
X5 MNAS-U 1.67 0.60 0.82 0.29 0.28 0.45 0.4 0.79/0.49 0.11 
X6 MNPS 0.43 1.10 0.75 0.47 0.44 0.35 0.56 0.33 0.94/0.62 
Note: Composite Reliabilities (CR) and Average Variance Extracted (AVE) are shown in bold on the Diagonal (CR/AVE). Correlations 
are shown on the lower matrix while squared correlations are shown on the upper matrix. 
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APPENDIX E
 Table 5 
Concurrent validation of the Medication Non-Adherence Scale 
Dependent variable: Patients-specific mean PDC 
Parameter Estimatec Std. Error p-value 
Model with MNAS sub-scale scores as independent variables (R2 = 0.0587) 
Intercept 90.94 4.10 <0.01 
MNAS-I-Side-effects -0.16 0.40 0.69 
MNAS-I-Addiction 0.85 0.86 0.32 
MNAS-I-Cost -1.94 0.54 < 0.01 
MNAS-I-Need -0.71 0.40 0.08 
MNAS-U -0.34 0.27 0.17 
Model with overall MNAS score as independent variable (R2 = 0.0453) 
Intercept 91.17 4.11 < 0.01 
MNAS -0.50 0.10 < 0.01 
c The estimates have been adjusted for ‘age’. 
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APPENDIX F 
 Table 6 
Concurrent validation of the Medication Non-Persistence Scale 
Dependent variable: Standardized patient-specific mean days to discontinuation 
Parameter Estimatee Std. Error p-value 
Model with original MNPS score (R2 = 0.0089) 
Intercept 85.32 3.95 <0.01 
MNPS -0.84 0.67 0.21 
Model with dichotomous MNPS score (R2 = 0.0132) 
Intercept 86.23 3.96 <0.01 
MNPS-Dichotomous 
(non-persistent vs. persistent) 
-3.97 1.86 0.03 
e The estimates have been adjusted for ‘age’. 
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APPENDIX G 
 Medication Non-Adherence Scale (MNAS) 
Over the past SIX MONTHS, how often have you done the following things without being advised to do so by your doctor? 
Please respond to all of the following statements by selecting Never, Rarely, Sometimes, Often, or Always. 
 Never Rarely Sometimes Often Always 
I forgot to take a dose of my medication.      
I skipped a dose of my medication because I was worried about its side effects.      
I skipped a dose of my medication because I was having side effects.      
I skipped a dose of my medication because I was feeling better.      
I skipped a dose of my medication because I was worried about getting addicted to it.      
I skipped a dose of my medication because I did not need it.      
I skipped a dose of my medication because I was worried about costs.      
I took a smaller amount of my medication because I was worried about its side effects.      
I took a smaller amount of my medication because I was having side effects.      
I took a smaller amount of my medication because I was feeling better.      
I took a smaller amount of my medication because I was worried about getting addicted to it.      
I took a smaller amount of my medication because I did not need it.      
I took a smaller amount of my medication because I was worried about costs.      
I missed a dose of my medication by mistake.      
I missed a dose of my medication because I did not get it refilled before I ran out.      
I missed a dose of my medication because I forgot to take it with me.      
  
1
0
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APPENDIX H
 Medication Non-Persistence Scale (MNPS) 
Sometimes, people stop taking their medication. Have you done the following things in the past ONE YEAR without being advised 
to do so by your doctor? Please circle your responses. 
I stopped taking my medication because I was worried about its side effects. Yes No 
I stopped taking my medication because I was having side effects. Yes No 
I stopped taking my medication because I was feeling better. Yes No 
I stopped taking my medication because I was worried about getting addicted to it. Yes No 
I stopped taking my medication because I did not need it anymore. Yes No 
I stopped taking my medication because I did not want to take it. Yes No 
I stopped taking my medication because it was inconvenient. Yes No 
I stopped taking my medication because I was worried about costs. Yes No 
I stopped taking my medication because the medication did not work. Yes No 
 
 
1
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* As the MNPS items are dichotomous, the Kuder-Richardson 20 reliability measure will be equivalent to the 
coefficient alpha. 
† The National Committee for Quality Assurance (NCQA) recommends the calculation of proportion of days 
covered (PDC) for medications indicated for these three conditions. This measure is an essential component of the 
measurement of health care quality, and is used by CMS and some other payers to enhance reimbursement to 
providers.53 As an adaptation of the NCQA PDC measure will be used as the criterion measure to validate the 
MNAS, the authors believe that limiting the study sample to these three conditions is justified. 
‡ The difference between the NCQA PDC measure and the adaptation used in this study was the length of the 
observation period – 12 months and 6 months, respectively. Due to this difference in observation period, the 
minimum drug coverage period used was also shorter – 150 days for the NCQA measure and 90 days of the 
adaptation. 
§ A month was assumed to be a 30 day period for this study. 
** Due to the dichotomous nature of the MNPS items, a maximum likelihood estimation model was deemed 
inappropriate. 
†† Univariable linear regressions were conducted using each measured demographic variable as an independent 
variable and the patient-specific mean PDC (or the standardized patient-specific days to discontinuation measure) as 
the dependent variable. Variables that demonstrated statistically significant results were included in model as 
‘important demographic variables’. 
‡‡ A 95% criteria was chosen rather than the conventional 80% criteria40,52,77 to enable better correspondence with 
the wording and scoring of MNAS items. 
§§ After looking at item distributions by using PROC UNIVARIATE in SAS 9.4, it was observed that most MNAS 
items had a skewed distribution. Thus, two methods were implemented to confirm the results of maximum 
likelihood estimation. First, the items were log transformed and estimated using maximum likelihood. Second, 
Mplus 7.3 was used to conduct a CFA with robust weighted least squares (WLSMV – weighted least squares with 
mean and variance adjustment).78–80 Both methods yielded identical factor structures. Thus to enable calculation of a 
summated score by assuming that the items are linear, the model estimated using maximum likelihood was finalized. 
*** Most MNAS items and the patient-specific PDC measure had a skewed distribution. Thus, two methods were 
used to confirm the results of this regression. First, the patient-specific PDC measure was log transformed, and the 
model was re-run. Second, the model was re-run using PROC GENMOD with a log link and a Gamma distribution. 
Both methods yielded qualitatively identical results. The original ordinary least squares model was thus finalized to 
enable ease of interpretation of results. 
††† This cut-off point was not decided based on the best Youden’s J (which would also have offered a cut-off point 
of 17), but by assessing the top five J values and deciding in the favor of better sensitivity, rather than specificity. 
This decision was made because when estimating non-adherence, false positives (getting identified as non-adherent 
when actually adherent) are not as severe a problem as false negatives (getting identified as adherent when actually 
non-adherent). 
‡‡‡ The socially desirable response bias assessment questions were not included in the study as many Pretest 3 
patients complained about the vague nature of those questions in the comments section. Upon finding no statistical 
evidence of such a bias in Pretest 3, the authors decided not to include those questions in the study to avoid any 
negative impact on the assessment of the non-adherence and non-persistence. 
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ABSTRACT 
 
Objective 
To assess the ability of the Medication Non-Adherence Scale (MNAS) in predicting future 
medication non-adherence. 
Design 
Prospective observational study 
Setting 
Three independent community pharmacies in the Southeastern United States. 
Participants 
Five hundred and seventy-nine patients, 18 years of age and older, who were prescribed at least 
one medication indicated for diabetes, hypertension, or dyslipidemia, and used one of the three 
pharmacies approached for most of their medications. 
Main outcome measure 
A 3-month adaptation of the National Committee for Quality Assurance (NCQA) proportion of 
days covered (PDC) measure. 
Results 
Three MNAS sub-scales – intentional non-adherence due to worries about medication cost 
(unstandardized regression coefficient = -1.17 (p = 0.02)), intentional non-adherence due to lack
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of perceived need of the medication (unstandardized regression coefficient = -0.75 (p < 0.05)), 
and unintentional non-adherence (unstandardized regression coefficient = -0.65 (p = 0.01)) – 
were observed to be statistically significantly associated with future medication non-adherence. 
The overall summated version of the MNAS was also observed to estimate future PDC 
(unstandardized regression coefficient = -0.62 (p < 0.005)). Results of the ROC curve analysis 
demonstrated that a score beyond 20 on the MNAS may indicate incidence of medication non-
adherence in the next three months.  
Conclusion 
This study demonstrated the ability of the MNAS in predicting medication non-adherence in the 
next three months after administration.
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INTRODUCTION 
 
 Medication non-adherence is an important issue in health care.1–6 Numerous studies have 
demonstrated its adverse effects on health care utilization in diseases such as myocardial 
infarction, diabetes mellitus, hypertension, hypercholesterolemia, and congestive heart failure.2–
4,6 Studies have also concluded that such behavior can lead to an increase in the cost of health 
care.2,6 Recent estimates indicate that an additional $317.4 billion may be attributable to non-
adherence.2 Moreover, a report by Horne et al. concluded that 30 to 60% of medications are not 
consumed as prescribed.5 Due to the expanse of this issue, numerous methods have been devised 
to measure the construct – direct patient observation, drug level in biological fluids / biological 
assays and biomarkers, pill counts, prescription refill records and administrative claims data, 
electronic monitoring, and self-report.7–15 
Some researchers propose that among the methods listed above, electronic monitoring 
using MEMS should be considered a ‘gold standard’ measure.15–17  But recent papers suggest 
that rather than anointing a gold standard, the choice of measure should depend on the 
measurement setting.10 Due to their feasibility and practicality, self-reported measures appear to 
be the only pertinent tool to measure medication non-adherence in a clinical practice setting, 
which is the focus on the current paper. In accordance with this claim, the National Collaborating 
Centre for Primary Care and the Royal College of General Practitioners (London, UK), and the
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National Institute of Health and Clinical Excellence (NICE) recommended the use of self-reports 
in this setting.18 
There are numerous self-reported measures of medication adherence in use in health care 
research and practice today – 1986 Morisky scale19, Medication Adherence Rating Scale 
(MARS)20, Brief Medication Questionnaire (BMQ)21, Brief Adherence Rating Scale (BARS)22, 
Morisky Medication Adherence Scale23, Medication Adherence Reasons Scale (MARS)24, etc. 
These measures have been developed to assess concurrent or past medication adherence 
behavior. But oftentimes, prediction of future medication non-adherence behavior is equally 
important. If estimated effectively, this may enable the implementation of interventions prior to 
the potential occurrence of non-adherence, and may prevent its aforementioned negative impact. 
Researchers have developed several instruments to help health care practitioners identify 
patients with a higher propensity of being non-adherent.25–50 For such an instrument to be usable 
in a wide range of practice settings, it must be disease non-specific. A review of the literature 
revealed five scales that have been developed for, or validated in, multiple chronic conditions – 
the Adherence 14 (A14) scale29, the Adherence Starts and Knowledge-20 (ASK-20) scale35, the 
Medical Adherence Measure (MAM)42, the Beliefs and Behaviour Questionnaire (BBQ)47, and 
the Adherence Estimator® (AE)48–50. The primary requirement of an instrument purporting to 
assess patients’ future medication non-adherence, is an acceptable level of predictive validity. 
Out of the five measures listed, the Adherence Estimator® (AE) is the only instrument that has 
been tested for its predictive validity using pharmacy claims data.48–50 The instrument has 
presented good psychometric properties and has yielded favorable results related to predictive 
validity. It is a 3-item instrument, and these items measure patients’ perceived importance of 
prescription medications, worries about potential side/adverse effects of the medications 
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consumed, and perceived financial burden. Thus, the AE assesses the patients’ proximal beliefs 
about intentional non-adherence.49  
Many researchers in recent years have stressed on the importance of distinguishing 
between different reasons for non-adherence.10,24,51 These are broadly divided into intentional 
and unintentional medication non-adherence.10,52–61 This distinction is important because the 
rationale for non-adherence is different in the case of its two forms. Thus, the methods needed to 
intervene and improve future adherence are different as well. Strategies to counter intentional 
non-adherence should focus on improving the patient-physician relationship, implementing 
techniques derived from health behavior models, etc., while reminder phone calls/text 
messages/emails, pills-boxes, etc. are more effective in the case of unintentional non-
adherence.10,52,59,60,62,63 Moreover, Unni and Farris found evidence for further segregation of 
intentional non-adherence into practicality issues, issues pertaining to a lack of perceived 
necessity, and concern belief issues.51 Despite the AE’s commendable psychometric performance 
and simplicity, the lack of an unintentional medication non-adherence component and some 
aspects of the intentional non-adherence component, limits its applicability in a practice setting. 
Thus, there is a need for a scale that can predict a larger spectrum of reasons for future 
medication non-adherence to aid in the implementation of appropriate strategies to improve 
patients’ medication-taking behavior. 
The Medication Non-Adherence Scale (MNAS) promises to offer these properties.64 It 
has been designed as a clinical practice setting administrable and disease non-specific measure of 
medication non-adherence. The scale has been demonstrated to distinguish between five reasons 
for non-adherence – worries about side effects, worries about addiction to the medication, 
worries about cost of the medication, lack of perceived need of the medication, and unintentional 
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non-adherence. It has been concurrently validated against an adaptation of the National 
Committee for Quality Assurance (NCQA) proportion of days covered (PDC) measure65, among 
patients prescribed medications indicated in diabetes, hypertension, and dyslipidemia. The 
MNAS is based on Barber’s adaptation of Reason’s model of accident causation55,56,66,67, and the 
suggestions offered by Medication Adherence Reasons Scale (MAR-Scale) developed by Unni 
and Farris24,51. The items on the scales can be viewed in the appendix. 
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METHODOLOGY 
 
Study Objectives and Study Design 
A prospective observational study was conducted to test the ability of the Medication 
Non-Adherence Scale (MNAS) in predicting future medication non-adherence. Specifically, this 
study had two objectives: 
 To assess the predictive validity of the MNAS using an adaptation of the NCQA PDC 
measure as an objective measure of future medication non-adherence.14,65,68 
 To calculate sensitivity and specificity of the MNAS in predicting future medication non-
adherence using receiver-operating characteristic (ROC) curves.69,70 
Prescription fill data were obtained from three independent community pharmacy in the 
Southeastern region of the US. Patrons of these pharmacies, who were prescribed at least one 
medication indicated for diabetes, hypertension, or dyslipidemia were administered a survey 
containing the MNAS. The survey data were linked to the prescription fill data, and used to meet 
the aforementioned objectives. 
 
Sample Design and Data Collection 
Three independent community pharmacies in the Southeastern region of the United States 
were approached to participate in the study. Upon approval of Data Use Agreements (DUAs), the 
pharmacies were asked to provide prescription fill data for the past 7 months. These data were
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used to identify the sample frame. Patients, identified only by a unique encrypted patient 
identifier (PTID), were selected based on whether they are 18 years of age or older, and filled at 
least one prescription for medications indicated for diabetes, hypertension, or dyslipidemia. 
Specifically, medications that fall under one of the seven therapeutic categories of interest 
specified by the National Committee for Quality Assurance (NCQA) were considered. These 
include beta-blockers (BBs), angiotensin-converting enzyme (ACE) inhibitors or angiotensin-
receptor blockers (ARBs), calcium channel blockers (CCBs), biguanides, sulfonylureas, 
thiazolidinediones, and statins.65 Survey instrument packets, containing a cover letter from the 
pharmacy patronized and the survey instrument (with the MNAS and demographic questions), 
were created for each patient in the sample frame. An independent data manager linked the 
PTIDs to the patients’ names and addresses, and printed address labels to be posted on the survey 
instrument packets. This was done to ensure that the researchers did not have access to the 
patients’ identities. These packets were mailed to the patients, and they were expected to mail 
back the completed instrument via the business reply mailer enclosed.* Four months after the 
date of receipt of the last usable survey, the pharmacies were asked to provide an amendment to 
the participants’ prescription fill data.† 
 
Data Management 
The survey data were linked to the prospective prescription fill data using PTID and an 
encrypted mailing ID (MID)‡ as linking variables. The resultant patient-fill level file was then 
aggregated to a patient-therapeutic category level file. This file was used to calculate the 
proportion of days covered (PDC) measure for each therapeutic category of interest specified by 
the National Committee for Quality Assurance (NCQA)65, using a 3-month prospective 
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prescription data measurement period. A 3-month period was used to improve the feasibility of 
the study. This 3-month period was patient specific, depending on, and starting from, the date of 
survey return postmark. The fourth month of prospective data were used to distinguish between 
potential non-adherence (i.e. if a prescription for a drug in the same therapeutic category is filled 
or refilled in this fourth month) and non-persistence (i.e. if such a fill or refill is not observed in 
this fourth month). Similarly, a 1-month period prior to the date of survey return postmark was 
observed to account for potential overlaps in fills or refills from that period. Based on the NCQA 
specifications, only participants that had drug coverage for a minimum of 60 days were included 
in this analysis. This file was further converted into a patient-level file, and the therapeutic 
category-specific PDCs were averaged to calculate patient-specific mean PDC scores. This file 
was used for data analysis. 
 
Data Analysis 
Data were analyzed using SAS 9.4. This study utilized the survey data collected in the 
study by Athavale et al, in their development of the MNAS.64 Results of confirmatory factor 
analysis, and the subsequent internal consistency reliability, and convergent and discriminant 
validity analyses conducted using these data have been elaborately explained by the authors in 
their paper titled ‘Development of the Medication Non-Adherence Scale (MNAS) and the 
Medication Non-Persistence Scale (MNPS)’64. In order to meet the first objective of this study – 
predictive validation of the MNAS – two multivariable linear regressions were conducted using 
the GLM procedure in SAS. In the first model, the summated MNAS sub-scales were used as 
independent variables, important demographic variables§ as control variables, and the patient-
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specific mean PDC variable as the dependent variable. In the second model, the MNAS sub-scale 
scores were replaced with the overall summated MNAS score. 
 To calculate sensitivity and specificity of the MNAS while predicting future medication 
non-adherence, the score on the scale was first divided into meaningful categories. This was 
done by constructing a receiver-operating characteristic (ROC) curve for the overall summated 
MNAS score. The patient-specific mean PDC variable was converted to a dichotomous 
adherence variable, assuming that patients with a score of 95% or above are adherent to their 
medications**, and used in the ROC curve analysis. The optimum cut-off point thus determined 
was used to calculate sensitivity and specificity. 
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RESULTS 
 
Sample Demographic Characteristics 
The sample frame contained 4,554 patients. After 40 days in the field, 831 completed 
survey responses were obtained, and 611 packets were returned by the postal service due to 
incomplete or outdated mailing addresses. Thus, a response rate of 21.08% was observed. Upon 
joining this file with the prescription fill data, and creating a patient-level file by averaging the 
therapeutic category-specific PDCs, 579 patients remained in the final sample used for analysis. 
Details about the sample used in this study can be viewed in Table 1. The inclusion 
criteria required the consumption of at least one prescription medication indicated for diabetes, 
hypertension, or dyslipidemia. Thus the average age of the sample was 65 years, and 64.1% of 
individuals were greater than 60 years of age. The sample was 57.3% female, 86.4% white, with 
64.8% indicating that they were currently married. About 24% indicated that they were college 
educated. About half the sample indicated that they earned less than $40,000. About 65% of the 
sample indicated that they consumed 3-8 chronic medications, with at least one of them 
prescribed for diabetes, hypertension, or dyslipidemia. More than 50% of the sample were 
insured by Medicare, private insurance, or both, and about 90% indicated that they would 
classify their health status as from ‘very good’ to ‘fair’. 
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Predictive Validity of the MNAS 
 As described earlier, two multivariable regression models were conducted to assess the 
predictive validity of the MNAS. The results of both models can be viewed in Table 2. The first 
model contained the five MNAS sub-scale scores as independent variables. The results of this 
model identified a statistically significant association between three MNAS sub-scales and the 
adapted NCQA patient-specific mean PDC measure – intentional non-adherence due to worries 
about medication cost (unstandardized regression coefficient = -1.17 (p = 0.02)), intentional non-
adherence due to lack of perceived need of the medication (unstandardized regression coefficient 
= -0.75 (p < 0.05)), and unintentional non-adherence (unstandardized regression coefficient = -
0.65 (p = 0.01)). The regression estimates indicated that a higher score on the sub-scales was 
associated with a lower PDC value, which was the expected direction. The second regression 
model utilized an overall summated MNAS score rather than the sub-scale scores. This model 
found evidence for a statistically significant association between such a summated score and the 
adapted NCQA PDC measure (unstandardized regression coefficient = -0.62 (p < 0.01)). The 
results of these two models provided the necessary evidence to conclude that the MNAS has 
predictive validity with the adapted NCQA PDC measure. 
 
Optimum Cut-off Point, Sensitivity, and Specificity 
A ROC curve was plot using the LOGISTIC procedure in SAS 9.4 to arrive at an 
optimum cut-off point for the MNAS when estimating future medication non-adherence. A c 
statistic of 0.63 was obtained. The top five Youden’s J values were assessed by comparing the 
resultant sensitivity, specificity, false positive, and false negative values generated. Considering 
that identifying a case of non-adherence (though at times incorrectly) is more important than 
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excluding adherent individuals, a decision was made to favor sensitivity over specificity, and a 
score of 20.7 on the overall summated MNAS was considered the optimal cut-off point. At this 
point, the scale had a sensitivity of 0.78 and specificity of 0.41. As the overall summated MNAS 
scale score can only be in the form of whole numbers, and for ease of interpretation in a practice 
setting, a cut-off point of 20 was finalized. At this point, the scale had a sensitivity of 0.72 and 
specificity of 0.48. 
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DISCUSSION 
 
A review of the literature conducted by the authors identified five scales that were disease 
non-specific, and designed to offer an estimate of future medication non-adherence behavior –
Adherence 14 (A14) scale29, Adherence Starts and Knowledge-20 (ASK-20) scale35, th Medical 
Adherence Measure (MAM)42, Beliefs and Behaviour Questionnaire (BBQ)47, and Adherence 
Estimator® (AE)48–50. But out of these, only the AE has been previously tested for its predictive 
validity.48–50 Also, despite having favorable psychometric properties, the AE leaves a few 
reasons for non-adherence unmeasured. Due to such a limited spectrum of reasons, appropriate 
tailoring of interventions to improve medication adherence may be hampered. 
The Medication Non-Adherence Scale (MNAS) has also demonstrated good 
psychometric properties, has been designed to be disease non-specific, and has been shown to 
distinguish between five reasons for non-adherence – intentional non-adherence due to worries 
about side-effects, intentional non-adherence due to worries about addiction to the medication, 
intentional non-adherence due to worries about cost of the medication, intentional non-adherence 
due to lack of perceived need for the medication, and unintentional non-adherence.64 This paper 
provides evidence for the use of the MNAS as an instrument to predict future medication non-
adherence. This scale has also been concurrently validated to estimate a 6-month measure of 
PDC.14,64,65,68 Thus by demonstrating the ability of the MNAS in predicting both, concurrent and
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future medication non-adherence, the evidence presented in this paper further improves the 
applicability of the scale in a practice setting. 
 
Interpretation for Results and Recommendations for Use in Practice 
 Out of the MNAS sub-scales, those concerned with worries about medication cost, lack 
of perceived need, and unintentional non-adherence, were seen to have a statistically significant 
impact on future medication non-adherence. When the 3-month measure of future PDC was 
regressed on the overall summated MNAS, it was observed that on average, for every 1 unit 
increase in the MNAS score, the PDC percentage decreased by 0.61 percent. Further, the ROC 
curve analysis revealed that on average a score beyond 20 on the MNAS estimated a PDC below 
95%. If a patient presents with such a score, his/her sub-scale responses must be considered to 
determine the type of intervention that is needed to improve medication adherence. Higher score 
on the unintentional non-adherence sub-scale will require reminders (SMS, email, phone call, 
etc.) to improve their adherence, while higher scores on the other sub-scales may require patient 
counselling to deal with the specific issue(s) at hand. If worries of medication cost is the primary 
driver of the overall summated MNAS score, either switching to cheaper generics, redirection to 
cost-saving programs from pharmaceutical companies, or patient counselling to improve the 
patient’s understanding of the importance of medication may be necessary. 
 
Limitations of the Scale and Directions for Future Research 
The first limitation of the present study is the potentially low external validity of the 
results. This study was conducted among patrons of three independent community pharmacies in 
the Southeastern region of the United States. Though the results presented here depict a robust 
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association between the scale and the objective measure of medication non-adherence used, the 
authors cannot make any claims about its applicability in other geographic and demographic 
settings. Future studies must assess the applicability of this scale in other samples to improve its 
validity. 
Athavale et al presented an elaborate account of pretests conducted to try and ensure the 
inclusion of all reasons for medication non-adherence.64 They also noted the absence of any 
evidence of socially desirable response bias in the measure.64 But the analysis conducted here 
indicates that the scale only explains 11.12% of the variation in future non-adherence. One 
reason for such a result may be found in the work published by Cole and colleagues.71,72 They 
state that most psychological constructs are composed of three components – state, trait, and 
occasion. In testing whether past behavior can predict future behavior, the current paper may 
only have estimated the ‘trait’ component of medication adherence; the unexplained variation in 
future PDC may be estimated by appropriately extracting the ‘state’ and ‘occasion’ components 
of the construct. Future research should test such a hypothesis to improve the self-reported 
measurement of medication adherence. 
Finally, though this study validates the MNAS using a generally accepted objective 
measure of medication adherence, it is necessary for future studies to comparatively assess the 
ability of other contemporary scales, particularly the Adherence Estimator® (AE)49, in predicting 
future PDC. Such an assessment will help establish a superior scale for this purpose. 
 
Conclusion 
 The Medication Non-Adherence Scale (MNAS) has been demonstrated to estimate 
concurrent64 as well as future medication non-adherence, and distinguish between different 
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reasons for the same in a disease non-specific context64. On account of its validation against the 
proportion of days covered (PDC) measure of medication adherence, it may offer health care 
practitioners a tool for enhancing their reimbursement from payers.†† Thus, the results elucidated 
by Athavale et al in their development of the MNAS64 and those presented here, build a 
compelling argument for the use the MNAS in health care practice and research. 
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APPENDIX A
 Table 1 
Description of sample demographic characteristics 
Demographic Characteristics # % 
Age 
<= 45 34 5.9% 
46 – 60 174 30.1% 
61 – 70 172 29.7% 
71 – 80 136 23.5% 
> 80 63 10.9% 
Gender 
Male 190 32.8% 
Female 332 57.3% 
Missing 57 9.8% 
Race 
White 500 86.4% 
Other races 76 13.1% 
Missing 3 0.5% 
Education 
Up to high school graduate 240 41.5% 
Some college (no degree), trade or technical school, or associate degree 192 33.2% 
Bachelors, professional, or graduate degree 142 24.5% 
Missing 5 0.9% 
Marital Status 
Married 375 64.8% 
Currently not married 203 34.8% 
Missing 1 0.2% 
Income Under $20,000 150 25.9% 
1
4
0
 
 $20,000 to $39,999.99 132 22.8% 
$40,000 to $59,999.99 82 14.2% 
$60,000 to $79,999.99 56 9.7% 
$80,000 or more 117 20.2% 
Missing 42 7.3% 
No. of Medications 
1 – 2 60 10.4% 
3 – 4 139 24.0% 
5 – 6 143 24.7% 
7 – 8 97 16.8% 
9 – 10 50 8.6% 
> 10 69 11.9% 
Missing 21 3.6% 
Health Insurance 
Medicare 339 50.2% 
Medicaid 66 9.8% 
Private 364 53.9% 
Uninsured 33 4.9% 
Tricare 6 0.9% 
Don’t know 6 0.9% 
Missing 4 0.6% 
Health Status 
Excellent 16 2.8% 
Very Good 137 23.7% 
Good 229 39.6% 
1
4
1
 
 Fair 158 27.3% 
Poor 37 6.4% 
Missing 2 0.3% 
 
1
4
2
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APPENDIX B
 Table 2 
Predictive validation of the Medication Non-Adherence Scale 
Dependent variable: Participants-specific mean PDC 
Parameter Estimatec Std. Error p-value 
Model with MNAS sub-scale scores as independent variables (R2 = 0.1112) 
Intercept 96.12 3.84 <0.01 
MNAS-I-Side-effects -0.53 0.39 0.18 
MNAS-I-Addiction 0.50 0.81 0.54 
MNAS-I-Cost -1.17 0.50 0.02 
MNAS-I-Need -0.75 0.37 <0.05 
MNAS-U -0.65 0.25 0.01 
Model with overall MNAS score as independent variable (R2 = 0.1058) 
Intercept 96.16 3.82 <0.01 
MNAS -0.61 0.10 <0.01 
c The estimates have been adjusted for age and race. 
1
4
4
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* This study uses the survey data collected in the paper by Athavale et al64. For a detailed explanation of the survey 
data collection methodology, please refer to their article titled ‘Development of the Medication Non-Adherence 
Scale (MNAS) and the Medication Non-Persistence Scale (MNPS)’. 
† Studies by Toy et al.73 and Benner et al.68 have assessed adherence at 3 months using PDCs. While Toy et al. 
concluded that in the case of a once-daily dose, the level of adherence does not change over time, Benner concluded 
that the PDC value decreases over time. 
‡ The MID was linked to the PTID, and was printed on each survey instrument. It was used to mask the survey 
responses from the independent data manager. The researchers possessed the crosswalk between the MID and the 
PTID, while the independent data manager possessed the crosswalk between the PTID and patients’ names and 
addresses. 
§ A series of univariable linear regressions were conducted using the patient-specific mean PDC as the dependent 
variable and each measured demographic variable as an independent variable. Variables that demonstrated a 
statistically significant relationship with the DV were termed ‘important demographic variables’. 
** A cut-off point of 95% was used rather than the traditional 80%68,74,75 based on the MNAS item wording. 
†† Proportion of days covered (PDC) is used by the Centers of Medicare & Medicaid (CMS)76, and many private 
insurers to determine pharmacy use quality, which in turn is used to determine reimbursement. 
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ABSTRACT 
 
Background 
There are numerous self-reported measures to estimate medication adherence. The Medication 
Non-Adherence Scale (MNAS) has offered promising results in estimating concurrent and future 
medication non-adherence. 
Objective 
To compare the ability of the MNAS, 1986 Morisky scale, and Medication Adherence Reasons 
Scale in estimating concurrent medication adherence, and the MNAS and Adherence Estimator® 
in estimating future medication adherence. 
Methods 
An observational study with retrospective and prospective phases was conducted among patrons 
of three independent community pharmacies in the Southeastern United States. A survey 
containing the scales to be assessed was administered to patients that have filled medications 
indicated for diabetes, hypertension, and/or dyslipidemia. The survey data were then linked to 
the patients’ prescription fill data. Univariable linear regressions were conducted using each 
scale as the independent variable, and the appropriate proportion of days covered (PDC) variant 
(6-month retrospective or 3-month prospective) as the dependent variable. The statistical 
significance (at α = 0.05), standardized regression coefficients, and R2s were compared, and the
148 
 
predicted values generated from each regression were used to assess whether the estimates 
generated by each scale are statistically significantly different from each other. 
Results 
In estimating concurrent PDC, the MNAS model generated an R2 of 0.043, and a standardized 
regression coefficient of -0.208, the Morisky scale model generated an R2 of 0.018, and a 
standardized regression coefficient of -0.134, and the MAR-Scale model generated an R2 of 
0.016, and a standardized regression coefficient of -0.125. In estimating future PDC, MNAS 
model generated an R2 of 0.083, and a standardized regression coefficient of -0.288, the AE 
model generated an R2 of 0.010, and a standardized regression coefficient of -0.099. Both 
relationships were found to be statistically significant. All estimates were also found to be 
statistically significantly different from those generated by the MNAS.  
Conclusions 
The MNAS was observed to perform better in estimating concurrent and future medication 
adherence than the comparator scales.
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INTRODUCTION 
 
 The negative impact of medication non-adherence has been studied extensively. The 
resultant health-related and economic adverse effects have been demonstrated in a wide range of 
chronic diseases such as hypertension, diabetes, hypercholesterolemia, congestive heart failure, 
and myocardial infarction.1–5 Numerous interventions have been devised to counter the issue of 
medication non-adherence.6–13 But in order to implement a successful intervention, effective 
measurement of the construct is necessary. 
 A meta-analysis conducted by Peterson and colleagues concluded that most medication 
adherence interventions occurred in a practice setting.8 According to the National Collaborating 
Centre for Primary Care and the Royal College of General Practitioners (London, UK), and the 
National Institute of Health and Clinical Excellence (NICE), self-reported questionnaires are best 
suited for measuring and identifying medication non-adherence in this setting.14 This point is 
also supported by Garfield and colleagues at the British Medical Association.15 A number of 
self-reported instruments have been developed over the past few decades to measure concurrent 
medication non-adherence, and predict the propensity of future non-adherence. These include the 
1986 Morisky scale16, Medication Adherence Reasons Scale (MAR-Scale)17, Medication 
Adherence Rating Scale (MARS)18, Brief Medication Questionnaire (BMQ)19, Brief Adherence 
Rating Scale (BARS)20, Morisky Medication Adherence Scale21, Adherence 14 (A14) scale22, 
Adherence Starts and Knowledge-20 (ASK-20) scale23, Medical Adherence Measure (MAM)24,
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Beliefs and Behaviour Questionnaire (BBQ)25, Adherence Estimator® (AE)26–28 etc. Out of these 
measures, the 1986 Morisky scale is the most prevalent in measuring concurrent medication non-
adherence in health care practice and research.16,29–34 Its popularity is a result of its ability to be 
used across multiple chronic diseases. It has been used in diseases like diabetes, hypertension, 
HIV, fibromyalgia, cardiovascular diseases, etc.29,30,32–34 Despite its prevalence, it has offered 
mixed results pertaining to internal consistency reliability.16,29–33 Morisky et al. published an 
updated version of their scale in 2009 to overcome some of the downfalls of its predecessor.21 
But the 2009 Morisky scale (Morisky Medication Adherence Scale) has twice the number of 
items as the 1986 scale, and based on our literature review, has only been tested in the 
hypertensive and diabetic populations.21,35–38 
 Recently, Unni and Farris developed the Medication Adherence Reasons Scale (MAR-
Scale) to help practitioners distinguish between the different reasons for non-adherence in the 
dyslipidemia and asthma.17,39 This scale categorizes the reasons for non-adherence into four 
factors – practicality issues (e.g. not being able to open the container, pharmacy being out of 
medicine, etc.), lack of necessity belief issues (e.g. perceived need for medication, perceived 
effectiveness of medication, etc.), concern belief issues (e.g. possible side-effects or long-term 
effects), and forgetfulness issues. Though this scale has demonstrated respectable reliability and 
validity, it is seen to perform differently across disease conditions17,39, and has only been 
validated against self-reported, “subjective” measures17,40. 
McHorney and colleagues developed the Adherence Estimator® (AE) in 2009.28 It is a 
three-item scale designed to capture the proximal beliefs about intentional non-adherence.28 The 
items measure perceived importance of medications, worries about adverse/side effects, and 
perceived financial burden. These items have been validated for identification of individuals who 
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have a propensity of being intentionally non-adherence to their medications in the future. The 
results have demonstrated a promising ability to predict future intentional non-adherence. In 
recent years, researchers have outlined the importance of assessing both, the intentional and 
unintentional, components of medication non-adherence.15,34,41–49 The AE does not incorporate 
the unintentional component of medication non-adherence, and based on the MAR-Scale, also 
some aspects of the intentional component. It also has not been shown to yield valid, reliable, or 
meaningful results across multiple medications.26,28 
The Medication Non-Adherence Scale (MNAS) is a self-reported measure of medication 
adherence which is designed to be practice setting administrable and disease non-specific.50 Its 
ability to predict concurrent medication non-adherence has been tested in patients prescribed 
medications for diabetes, hypertension, and dyslipidemia.50 It has presented with good 
psychometric properties, and can distinguish between five reasons for medication non-adherence 
– intentional non-adherence due to worries about side-effects, intentional non-adherence due to 
worries about addiction to the medication, intentional non-adherence due to worries about 
medication cost, intentional non-adherence due to lack of perceived need for the medication, and 
unintentional non-adherence.50 There is also evidence to suggest that the MNAS can predict 
future medication non-adherence over a 3-month period.51 Thus, the MNAS may help address 
some of the issues presented by the 1986 Morisky scale, the MAR-Scale, and the AE. 
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METHODOLOGY 
 
Study Objectives and Study Design 
 A retrospective observational study was conducted among patrons of three independent 
community pharmacies in the Southeastern region of the United States to compare the 
Medication Non-Adherence Scale (MNAS) with the 1986 Morisky scale and the Medication 
Adherence Reasons Scale (MAR-Scale), and a prospective observational study was conducted to 
compare the MNAS with the Adherence Estimator®* (AE). The items on the MNAS can be 
viewed in the appendix. The 1986 Morisky scale was chosen as a comparator while measuring 
concurrent medication non-adherence, as it is the most widely used scale for this purpose.16,29–34 
The MAR-Scale was also chosen as a comparator while measuring concurrent medication non-
adherence as it takes a similar approach for assessing the reasons for medication non-adherence 
as the MNAS, and has demonstrated good reliability and validity levels.17,39 The AE was chosen 
as a comparator while measuring future medication non-adherence, as according to our review of 
the literature, it is the only disease non-specific scale that has been tested for its predictive 
validity against an objective measure.22–28 Specifically, this study had the following objectives: 
 To compare the ability of the MNAS and the 1986 Morisky scale in predicting 
objectively measured concurrent medication non-adherence (using an adaptation of the 
NCQA proportion of days covered (PDC) measure52,53)
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 To compare the ability of the MNAS and the Medication Adherence Reasons Scale in 
predicting objectively measured concurrent medication non-adherence (using an 
adaptation of the NCQA proportion of days covered (PDC) measure52,53) 
 To compare the ability of the MNAS and the Adherence Estimator® in predicting 
objectively measured future medication non-adherence (using an adaptation of the NCQA 
proportion of days covered (PDC) measure52,53) 
 
Sample Design and Data Collection 
 Prescription fill data for the past one year were obtained from three community 
pharmacies in the Southeastern region of the US after Data Use Agreements (DUAs) were 
approved and signed. Patients that were 18 years or older, and were prescribed at least one 
medication indicated for diabetes, hypertension, or dyslipidemia were identified using an 
encrypted patient ID (PTID) assigned by an independent data manager†. The researchers 
specifically considered patients that started on one of seven therapeutic categories of interest 
specified by the National Committee for Quality Assurance (NCQA)54 at least 6 months prior to 
the end of data. These therapeutic categories include beta-blockers (BBs), angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), calcium channel blockers 
(CCBs), biguanides, sulfonylureas, thiazolidinediones, and statins.54 The independent data 
manager then linked these PTIDs to patient names and addresses. 
Survey instruments containing the MNAS, MNPS, a 5-point scale version of the 1986 
Morisky Scale17,39,55,56, the MAR-Scale17, AE28, and demographic questions, printed on a 
business reply mailers, were then printed for each patient in the sample frame. The survey 
instrument also contained a unique mailing ID (MID) assigned by the researchers, which was 
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patient specific, and linked to the PTID. The instrument was enclosed in an envelope with the 
appropriate name, address, and MID printed on it. The MID was used to mask the survey data 
from the independent data manager, and further protect patient privacy. After the receipt of 
completed surveys, the three pharmacies were asked to amend the prescription fill data to 4 
months after the end of the survey data collection period.  
 
Data Management 
 The survey data were manually entered into a Microsoft Excel file, and then linked to the 
prescription fill data using the MID and PTID such that there were 7 months of prescription fill 
data prior to the date of survey return post-marking (concurrent period), and 4 months after 
(predictive period).‡ These periods were patient-specific as the date of survey return post-mark 
was different for each patient. Patients who did not respond to items on the MNAS, the 5-point 
scale version of the 1986 Morisky scale, the MAR-Scale, were eliminated from the concurrent 
period dataset. Those who did not respond to the MNAS and AE were eliminated from the 
predictive period dataset. The past 6 months of prescription fill data were used to calculate the 
proportion of days covered (PDC) measure for each of the seven therapeutic categories of 
interest.52,57–59 A 6-month period was used in accordance with the recall period of the MNAS. 
PDCs were also calculated on the 3-month period after the date of survey return post-mark. 
Based on the NCQA guidelines for calculating PDCs, a minimum drug coverage of 90 days for 
the concurrent period, and 60 days for the predictive period, was deemed appropriate.54 The 
therapeutic category-specific concurrent and predictive period PDCs were then averaged to 
calculate patient-specific mean concurrent and predictive period PDCs. As the number of 
patients that met the minimum drug coverage period was expected to differ for the two periods, 
155 
 
two separate analysis files were created, one for the concurrent period, and another for the 
predictive period. 
 
Data Analysis 
SAS 9.4 was used for data analysis. In order to compare the MNAS and the 5-point 1986 
Morisky scale in predicting concurrent medication non-adherence, two linear regressions were 
conducted using the GLM procedure. The first model contained the overall summated MNAS 
score as the independent variable and the patient-specific mean concurrent period PDC as the 
dependent variable. The other model contained the adherence score obtained from the 5-point 
1986 Morisky scale as the independent variable and the patient-specific mean concurrent period 
PDC as the dependent variable. Upon running these analyses, statistical significance (at α = 
0.05), standardized regression coefficients, and R2s obtained from the two models were 
compared. The predicted values from the two regression models were saved into a separate SAS 
dataset. The relative effectiveness of the two scales in predicting the patient-specific mean 
concurrent period PDC was then statistically compared using the saved predicted values via the 
procedure outlined by Steiger.60,61 The MNAS and the MAR-Scale were compared in a manner 
identical to that mentioned above; the only difference being the replacement of the 5-point 1986 
Morisky scale score with the score on the MAR-Scale. 
The abilities of the MNAS and the Adherence Estimator® in predicting future medication 
non-adherence were then compared. For this, two linear regressions were conducted. The prior 
model included the overall MNAS score as independent variable and the patient-specific mean 
predictive period PDC as the dependent variable. The latter model included a categorical version 
of the score on the AE§ as the independent variable and the patient-specific mean predictive 
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period PDC served as the dependent variable. The GLM procedure was used for these analyses. 
The ordered categories in the AE variable were treated quantitatively for this analysis. The two 
scales were then compared using the method explained in the preceding paragraph (i.e. while 
comparing the MNAS and the 5-point 1986 Morisky scale). 
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RESULTS 
 
Sample Characteristics 
 The sample frame consisted of 4,554 patients. Survey instrument packets were created for 
each of these patients, and mailed. At the end of a 40 day data collection period, 831 completed 
responses were obtained. 611 packets were returned by the postal service due to improper 
addresses. Thus a 21.08% response rate was observed (831 ÷ (4,554-611)). After joining the 
prescription fill data to the data from the completed survey responses, the concurrent period file 
contained 666 patients, while the predictive period file contained 567. 
The samples consisted of an older demographic with 64.1% (in both samples) reporting 
an age of greater than 60 years. About 30% of patients in either sample reported their age to be 
between 46 and 60 years. Both samples had a greater proportion of females (56.3% in the 
concurrent period sample and 57.3% in the predictive period sample), and about 87% reported 
their race as ‘white’. Approximately 26% of the concurrent period sample and 24% of the 
predictive period sample reported having at least a bachelor’s degree. About 65% in either 
sample reported their marital status as ‘married’, and about 48% reported an annual household 
income below $40,000. Approximately 65% of patients in both samples reported being 
prescribed 3-8 medications for chronic conditions. Most patients were privately insured (61.9% 
in the concurrent period and 53.1% in the predictive period), insured by Medicare (56.6% in the
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concurrent period and 49.5% in the predictive period), or by both. About 40% of patients in 
either sample reported their general health status as being ‘good’. 
 
Comparison with the 1986 Morisky Scale 
In order to compare the 1986 Morisky scale with the MNAS, two regression models were 
run. The MNAS model generated an R2 of 0.04, and a standardized regression coefficient of -
0.21 while the Morisky scale model generated an R2 of 0.02, and a standardized regression 
coefficient of -0.13. Relationships between the scales and the patient-specific mean concurrent 
period PDC were found to be statistically significant at α = 0.05. These results can be viewed in 
Table 2. The method proposed by Steiger60 was implemented to statistically compare the relative 
effectiveness of the two scales in predicting the patient-specific mean concurrent period PDC. 
The results of this analysis indicated that there was a statistically significant difference in the 
relative effectiveness of the two scales (p = 0.01). Based on these results, the authors concluded 
that the MNAS is more effective in estimating concurrent PDCs than the 1986 Morisky scale. 
 
Comparison with the Medication Adherence Reasons Scale 
The MAR-Scale and the MNAS were compared using two regression models. The results 
of this comparison can be viewed in Table 2. The model with the overall summated MNAS score 
generated a higher R2 value (0.04 versus 0.02 for the MAR-Scale) and a higher absolute value of 
the standardized regression coefficient (0.21 versus 0.12 for the MAR-Scale). Both relationships 
were found to be statistically significant at α = 0.05. Further, the two scales were compared using 
the method outlined by Steiger.60 The results of this analysis indicated that the comparative 
effectiveness of the two scales in predicting PDCs was statistically significantly different (p = 
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0.03). Thus, these analysis indicate that the MNAS is more effective in estimating PDCs than the 
MAR-Scale. 
 
Comparison with the Adherence Estimator® 
 The MNAS was compared with the AE in predicting future medication non-adherence 
measured using an adaptation of the NCQA PDC algorithm. This was done using two linear 
regressions. The results of these regression models can be viewed in Table 2. The MNAS model 
generated an R2 of 0.08, while the AE model generated an R2 of 0.01.** The relationship between 
the overall summated MNAS score and the patient-specific mean predictive period PDC was 
found to be statistically significant with a standardized regression coefficient of -0.29. The 
relationship between the AE and the patient-specific mean predictive period PDC was also 
observed to be statistically significant (at α = 0.05) with a standardized regression coefficient of -
0.10. Also, when the effectiveness of the two scales in predicting PDCs was compared using the 
method proposed by Steiger60, their predictive ability was statistically significantly different (p < 
0.01). These analyses indicate that the MNAS is more effective in predicting patient-specific 
mean predictive period PDCs than the AE. 
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DISCUSSION 
 
 Medication non-adherence has been demonstrated to have detrimental health and 
economic effects in a variety of chronic diseases – hypertension, diabetes, hypercholesterolemia, 
congestive heart failure, and myocardial infarction.1–5 Due to the awareness of this impact, 
numerous self-reported measured have been developed to estimate medication non-adherence, 
both concurrently and predictively, in research and practice.16–25,28 The Medication Non-
Adherence Scale (MNAS) has demonstrated good internal consistency reliability, and 
convergent and discriminant validity. Paper 1 and 2 also presented evidence for its concurrent 
and predictive validity in estimating PDC. The purpose of the current paper was to assess the 
comparative effectiveness of the MNAS and contemporary medication adherence, and 
medication adherence propensity scales, in predicting concurrent and future PDCs, respectively. 
The results presented here suggest that the MNAS performs better than the 5-point scale version 
of the 1986 Morisky Scale17,39,55,56, the Medication Adherence Reasons Scale17, and Adherence 
Estimator®28. 
 
Interpretation of Results 
 The MNAS was observed to perform better in estimating PDCs in both periods. It offered 
the highest R2 values – 0.04 in the concurrent period and 0.08 in the predictive period; it 
explained 4.3% of the variation in patient-specific mean concurrent period PDC, and 8.3% of the
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variation in patient-specific mean predictive period PDC. The MNAS had a standardized 
regression coefficient of -0.21 in the concurrent period and -0.29 in the predictive period. This 
indicates that for every standard deviation unit increase in the MNAS scale score, the value of 
the patient-specific mean PDC decreases by 0.21 standard deviation units in the concurrent 
period, and 0.29 standard deviation units in the predictive period. This decrease was lesser in the 
case of the comparator scales – 0.13 for the 5-point variant of the 1986 Morisky scale, 0.12 for 
the MAR-Scale, and 0.04 for the Adherence Estimator®. Though the 1986 Morisky scale and the 
MAR-Scale had inferior abilities to estimate mean PDC, these relationships were observed to be 
statistically significant. The Adherence Estimator® also demonstrated a statistically significant 
relationship with patient-specific mean predictive period PDC, but the MNAS offered higher 
standardized regression coefficients and R2s. Furthermore, a comparison of the predictive 
abilities of the scales using the method proposed by Steiger60 indicated that the estimates offered 
by the MNAS were statistically significantly better than those offered by 1986 Morisky Scale 
and MAR-Scale in predicting concurrent period PDCs, and those offered by the AE in predicting 
predictive period PDCs. 
 
Limitations of the Study and Directions for the Future 
 This study was conducted among patrons of three independent community pharmacies in 
the Southeastern United States. This may limit the generalizability of the scale. Future 
researchers should apply the MNAS in various socio-demographic and geographic settings to 
assess its external validity. Though the current study is conducted among disease categories that 
are of primary interest to health care providers and payers, MNAS should also be tested in other 
disease conditions to further improve on its generalizability. 
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 Though the MNAS performed better than the comparator scales, it is longer than the 
1986 Morisky scale and the Adherence Estimator®, thus potentially more cumbersome to 
administer. A shorter scale is usually desired in a practice setting. Thus future researchers should 
develop ‘short-form’ variant of the MNAS to overcome this drawback of the scale. 
 Another observation that must be made based on the results presented here, is the low 
values of R2 obtained for all self-reported measures in predicting PDCs. Considering the fact that 
the scale underwent multiple rounds of qualitative and quantitative pretest evaluations prior to 
this analysis minimizes the likelihood of the reason for such a result being unaccounted reasons 
for medication non-adherence or socially desirable response bias.50 The authors believe that such 
a result may have been observed due to a lack of items that measure medication non-adherence 
due to over-dosing. PDC calculations not only account for gaps in fills, but also overlaps. Thus 
accounting for such over-dosing may improve the amount of variation explained in PDC.  Future 
research should include an ‘over-dosing’ factor in the MNAS and reassess its concurrent and 
predictive validity against PDC. 
 
Conclusion 
 This paper presented a comparative estimation of an adaptation of the concurrently 
measured National Committee for Quality Assurance (NCQA) proportion of days covered (PDC) 
measure of medication adherence by the Medication Non-Adherence Scale (MNAS), a 5-point 
version of the 1986 Morisky scale, and the Medication Adherence Reasons Scale (MAR-Scale). 
Results of a comparative prediction of the adapted future PDC measure by the MNAS and the 
Adherence Estimator® (AE) were also described here. These analyses provided evidence for the 
statistical superiority of the MNAS in estimating both, concurrent and future, medication 
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adherence (as measured by the adapted PDC measure), over the other scales used in this study. 
Based on these results, and those obtained by Athavale et al in the MNAS developmental 
papers50,51, the Medication Non-Adherence Scale offers health care practitioners and researchers 
a valuable tool to improve patient health. 
 
164 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY
165 
 
1.  Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect 
of medication nonadherence on hospitalization and mortality among patients with diabetes 
mellitus. Arch Intern Med [Internet]. 2006 Sep 25;166(17):1836–41. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17000939 
2.  Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of 
medication therapy discontinuation on mortality after myocardial infarction. Arch Intern 
Med [Internet]. 2006 Sep 25;166(17):1842–7. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17000940 
3.  Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence 
on hospitalization risk and healthcare cost. Med Care [Internet]. 2005 Jun;43(6):521–30. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15908846 
4.  Horne R, Weinman J, Barber N, Elliott R, Morgan M, Cribb A, et al. Concordance, 
Adherence and Compliance in Medicine Taking: Report for the National Co-ordinating 
Centre for NHS Service Delivery and Organisation R & D (NCCSDO). Southampton, 
UK; 2005 p. 129.  
5.  Elliott R. Non-adherence to medicines: not solved but solvable. J Health Serv Res Policy 
[Internet]. 2009 Jan [cited 2012 Jul 12];14(1):58–61. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19103918 
6.  Bender B, Milgrom H, Apter A. Adherence intervention research: what have we learned 
and what do we do next? J Allergy Clin Immunol. 2003;112(3):489–94.  
7.  Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and cognitive-
behavioral intervention to improve HIV medication adherence among hazardous drinkers: 
a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46(4):443–50.  
8.  Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve 
medication adherence. Am J Heal Pharm. 2003;60(April):657–65.  
9.  Wu J-R, Corley DJ, Lennie TA, Moser DK. Effect of a medication-taking behavior 
feedback theory-based intervention on outcomes in patients with heart failure. J Card Fail 
[Internet]. Elsevier Inc; 2012 Jan [cited 2012 Mar 1];18(1):1–9. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3246219&tool=pmcentrez&re
ndertype=abstract 
10.  Munro S, Lewin S, Swart T, Volmink J. A review of health behaviour theories: how 
useful are these for developing interventions to promote long-term medication adherence 
for TB and HIV/AIDS? BMC Public Health [Internet]. 2007 Jan [cited 2012 Jul 
15];7:104–19. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1925084&tool=pmcentrez&re
ndertype=abstract 
166 
 
11.  McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to 
medication prescriptions. J Am Med Assoc. 2002;288(22):2868–79.  
12.  Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing 
medication adherence. Cochrane Database Syst Rev [Internet]. 2008 Jan [cited 2012 Jul 
12];(2):CD000011. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18425859 
13.  Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication 
adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. J Am 
Med Assoc. 2006;296(21):2563–71.  
14.  Nunes V, Neilson J, O’Flynn N, Calvert N, Kuntze S, Smithson H, et al. Clinical 
Guidelines and Evidence Review for Medicines Adherence: involving patients in 
decisions about prescribed medicines and supporting adherence. London, UK; 2009.  
15.  Garfield S, Clifford S, Eliasson L, Barber N, Willson A. Suitability of measures of self-
reported medication adherence for routine clinical use: a systematic review. BMC Med 
Res Methodol [Internet]. BioMed Central Ltd; 2011 Jan [cited 2012 Mar 31];11(1):149–
57. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3219622&tool=pmcentrez&re
ndertype=abstract 
16.  Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported 
measure of medication adherence. Med Care. 1986;24(1):67–74.  
17.  Unni EJ, Olson JL, Farris KB. Revision and validation of Medication Adherence Reasons 
Scale (MAR-Scale). Curr Med Res Opin [Internet]. Informa UK Ltd. London; 2013 Oct 
30 [cited 2013 Oct 15];1–11. Available from: 
http://informahealthcare.com/doi/abs/10.1185/03007995.2013.851075?journalCode=cmo 
18.  Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication 
Adherence Rating Scale (MARS) for the psychoses. Schizophr Res [Internet]. 2000 May 
5;42(3):241–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10785582 
19.  Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: 
a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 
[Internet]. 1999 Jun;37(2):113–24. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/14528539 
20.  Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS) 
validated against electronic monitoring in assessing the antipsychotic medication 
adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr Res 
[Internet]. 2008 Mar [cited 2012 Jul 18];100(1-3):60–9. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18255269 
167 
 
21.  Morisky DE, Ang A, Krousel-Wood M. Predictive validity of a medication adherence 
measure in an outpatient setting. J Clin Hypertens. 2009;10(5):348–54.  
22.  Jank S, Bertsche T, Schellberg D, Herzog W, Haefeli WE. The A14-scale: development 
and evaluation of a questionnaire for assessment of adherence and individual barriers. 
Pharm World Sci [Internet]. 2009 Aug [cited 2013 Apr 18];31(4):426–31. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19381860 
23.  Hahn SR, Park J, Skinner EP, Yu-Isenberg KS, Weaver MB, Crawford B, et al. 
Development of the ASK-20 adherence barrier survey. Curr Med Res Opin [Internet]. 
2008 Jul [cited 2013 Apr 18];24(7):2127–38. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18554431 
24.  Zelikovsky N, Schast AP. Eliciting accurate reports of adherence in a clinical interview: 
development of the Medical Adherence Measure. Pediatr Nurs [Internet]. 2008;34(2):141–
6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18543839 
25.  George J, Mackinnon A, Kong DCM, Stewart K. Development and validation of the 
Beliefs and Behaviour Questionnaire (BBQ). Patient Educ Couns [Internet]. 2006 Dec 
[cited 2013 Apr 18];64(1-3):50–60. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16843634 
26.  McHorney CA, Victor Spain C, Alexander CM, Simmons J. Validity of the adherence 
estimator in the prediction of 9-month persistence with medications prescribed for chronic 
diseases: a prospective analysis of data from pharmacy claims. Clin Ther [Internet]. 
Excerpta Medica Inc.; 2009 Nov [cited 2013 Apr 17];31(11):2584–607. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20110004 
27.  Gadkari A, McHorney C. PHP2: Validity of the Adherence Estimator in the prediction of 
persistence with chrnonic medications assessed over 14 months. ISPOR 15th Annual 
International Meeting [Internet]. Atlanta, GA: International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR); 2010 [cited 2013 Apr 17]. 
Available from: http://linkinghub.elsevier.com/retrieve/pii/S1098301510723858 
28.  McHorney CA. The Adherence Estimator: a brief, proximal screener for patient 
propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin 
[Internet]. 2009 Jan [cited 2012 Oct 5];25(1):215–38. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19210154 
29.  Pratt RJ, Robinson N, Loveday HP, Pellowe CM, Franks PJ, Hankins M, et al. Adherence 
to antiretroviral therapy: appropriate use of self-reporting in clinical practice. HIV Clin 
Trials [Internet]. 2001;2(2):146–59. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/11590523 
30.  Sewitch MJ, Leffondré K, Dobkin PL. Clustering patients according to health perceptions: 
relationships to psychosocial characteristics and medication nonadherence. J Psychosom 
168 
 
Res [Internet]. 2004 Mar [cited 2012 Jul 19];56(3):323–32. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15046970 
31.  Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying 
nonadherence with cardiovascular medications. Ann Pharmacother [Internet]. 2004 Sep 
[cited 2012 Jul 19];38(9):1363–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15238622 
32.  Elixhauser A, Eisen SA, Romeis JC, Homan SM. The effects of monitoring and feedback 
on compliance. Med Care [Internet]. 1990 Oct [cited 2012 Jul 19];28(10):882–93. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/2232919 
33.  Holzemer WL, Corless IB, Nokes KM, Turner JG, Brown MA, Powell-Cope GM, et al. 
Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient 
Care STDS. 1999;13(3):185–97.  
34.  Lowry KP, Dudley TK, Oddone EZ, Bosworth HB. Intentional and unintentional 
nonadherence to antihypertensive medication. Ann Pharmacother [Internet]. 2005 [cited 
2012 Jul 22];39(7-8):1198–203. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15956238 
35.  Al-Qazaz HK, Hassali MA, Shafie AA, Sulaiman SA, Sundram S, Morisky DE. The 
eight-item Morisky Medication Adherence Scale MMAS: translation and validation of the 
Malaysian version. Diabetes Res Cinical Pract [Internet]. Elsevier Ireland Ltd; 2010 Nov 
[cited 2013 Jun 5];90(2):216–21. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3109726&tool=pmcentrez&re
ndertype=abstract 
36.  Sakthong P, Chabunthom R, Charoenvisuthiwongs R. Psychometric properties of the Thai 
version of the 8-item Morisky Medication Adherence Scale in patients with type 2 
diabetes. Ann Pharmacother [Internet]. 2009 May [cited 2013 Jun 5];43:950–7. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/19366872 
37.  Muntner P, Joyce C, Holt E, He J, Morisky DE, Webber LS, et al. Defining the minimal 
detectable change in scores on the eight-item Morisky Medication Adherence Scale. Ann 
Pharmacother [Internet]. 2011 May [cited 2013 Jun 5];45:569–75. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21521862 
38.  Krousel-Wood MA, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to and 
determinants of medication adherence in hypertension management: perspective of the 
cohort study of medication adherence among older adults (CoSMO). Med Clin North Am. 
2009;93(3):753–69.  
39.  Unni EJ, Farris KB. Development of a new scale to measure self-reported medication 
nonadherence. Res Soc Adm Pharm [Internet]. Elsevier Inc; 2009; Available from: 
http://dx.doi.org/10.1016/j.sapharm.2009.06.005 
169 
 
40.  Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of 
medication adherence among seniors. Ann Pharmacother [Internet]. 2004 Feb [cited 2012 
Mar 28];38(2):303–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14742770 
41.  Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, et al. Stages of change 
for adherence with medication regimens for chronic disease: development and validation 
of a measure. Clin Ther [Internet]. 2000 Jul;22(7):858–71. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/10945512 
42.  Wroe AL. Intentional and unintentional nonadherence: a study of decision making. J 
Behav Med [Internet]. 2002 Aug;25(4):355–72. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/12136497 
43.  Barber N. Should we consider non-compliance a medical error? Qual Saf Health Care 
[Internet]. 2002 Mar;11(1):81–4. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1743570&tool=pmcentrez&re
ndertype=abstract 
44.  Barber N, Safdar A, Franklin BD. Can human error theory explain non-adherence? Pharm 
World Sci [Internet]. 2005 Aug;27(4):300–4. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16228628 
45.  Horne R. Compliance, adherence, and concordance: implications for asthma treatment. 
Chest [Internet]. 2006 Jul 1 [cited 2012 Jul 22];130(1 Suppl):65S – 72S. Available from: 
http://journal.publications.chestnet.org/article.aspx?articleid=1210785 
46.  Iihara N, Kurosaki Y, Miyoshi C, Takabatake K, Morita S, Hori K. Comparison of 
individual perceptions of medication costs and benefits between intentional and 
unintentional medication non-adherence among Japanese patients. Patient Educ Couns 
[Internet]. 2008 Feb [cited 2012 Jul 22];70(2):292–9. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18068938 
47.  Lehane E, McCarthy G. Intentional and unintentional medication non-adherence: a 
comprehensive framework for clinical research and practice? A discussion paper. Int J 
Nurs Stud [Internet]. 2007 Nov [cited 2012 Jul 22];44(8):1468–77. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16973166 
48.  Lehane E, McCarthy G. An examination of the intentional and unintentional aspects of 
medication non-adherence in patients diagnosed with hypertension. J Clin Nurs [Internet]. 
2007 Apr [cited 2012 Jul 22];16(4):698–706. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17402951 
49.  Schüz B, Marx C, Wurm S, Warner LM, Ziegelmann JP, Schwarzer R, et al. Medication 
beliefs predict medication adherence in older adults with multiple illnesses. J Psychosom 
Res [Internet]. Elsevier Inc.; 2011 Feb [cited 2012 Jul 22];70(2):179–87. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21262421 
170 
 
50.  Athavale AS, Bentley JP, Banahan III BF, McCaffrey DJ, Vorhies DW. Development of 
the Medication Non-Adherence Scale (MNAS) and the Medication Non-Persistence Scale 
(MNPS). [University, MS]: The University of Mississippi; 2015. p. 49.  
51.  Athavale AS, Banahan III BF, Bentley JP, McCaffrey DJ, Vorhies DW. Predictive 
validation of the Medication Non-Adherence Scale (MNAS). The University of 
Mississippi; 2015. p. 29.  
52.  Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy 
administrative databases: a proposal for standard definitions and preferred measures. Ann 
Pharmacother [Internet]. 2006 [cited 2012 Jul 21];40(7-8):1280–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16868217 
53.  Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term 
persistence in use of statin therapy in elderly patients. J Am Med Assoc [Internet]. 
2002;288(4):455–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12132975 
54.  National Committee for Quality Assurance. Pharmacy Measures. 2010 p. 9–17.  
55.  Brooks CM, Richards JM, Kohler CL, Soong S-J, Martin B, Windsor RA, et al. Assessing 
adherence to asthma medication and inhaler regimens: a psychometric analysis of adult 
self-report scales. Med Care. 1994;32(3):298–307.  
56.  Erickson SR, Coombs JH, Kirking DM, Azimi AR. Compliance from self-reported versus 
pharmacy claims data with metered-dose inhalers. Ann Pharmacother. 2001;35:997–1003.  
57.  Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Prospective validation 
of eight different adherence measures for use with administrative claims data among 
patients with schizophrenia. Value Heal [Internet]. 2009 Sep;12(6):989–95. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/19402852 
58.  Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist 
for medication compliance and persistence studies using retrospective databases. Value 
Heal [Internet]. 2007;10(1):3–12. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17261111 
59.  Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting 
measures of adherence with simple drug use, medication switching, and therapeutic 
duplication. Ann Pharmacother [Internet]. 2009 Jan [cited 2013 May 21];43(1):36–44. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/19126828 
60.  Steiger JH. Tests for comparing elements of a correlation matrix. Psychol Bull [Internet]. 
1980;87(2):245–51. Available from: http://content.apa.org/journals/bul/87/2/245 
61.  Tabachnick BG, Fidell LS. Comparing two sets of predictors. Using Multivariate 
Statistics. 6th ed. New York, NY: Pearson Education, Inc.; 2013. p. 153–4.  
171 
 
62.  U.S. Department of Health and Human Services. Understanding Health Information 
Privacy [Internet]. U.S. Department of Health and Human Services; [cited 2014 Oct 1]. 
Available from: http://www.hhs.gov/ocr/privacy/hipaa/understanding/index.html  
172 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF APPENDICES
173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX A
 Table 1 
Description of sample demographic characteristics 
Demographic Characteristics 
Concurrent 
Period 
Predictive 
Period 
# % # % 
Age 
<= 45 43 6.5% 34 5.9% 
46 – 60 196 29.4% 174 30.1% 
61 – 70 192 28.8% 172 29.7% 
71 – 80 157 23.6% 136 23.5% 
> 80 78 11.7% 63 10.9% 
Gender 
Male 223 33.5% 190 32.8% 
Female 375 56.3% 332 57.3% 
Missing 68 10.2% 57 9.8% 
Race 
White 583 87.5% 500 86.4% 
Other races 81 12.2% 76 13.1% 
Missing 2 0.3% 3 0.5% 
Education 
Up to high school graduate 270 40.5% 240 41.5% 
Some college (no degree), trade or technical school, or associate degree 215 32.3% 192 33.2% 
Bachelors, professional, or graduate degree 175 26.3% 142 24.5% 
Missing 6 0.9% 5 0.9% 
Marital Status 
Married 431 64.7% 375 64.8% 
Currently not married 234 35.1% 203 35.1% 
1
7
4
 
 1
7
5
 
Missing 1 0.2% 1 0.2% 
Income 
Under $20,000 161 24.2% 150 25.9% 
$20,000 to $39,999.99 161 24.2% 132 22.8% 
$40,000 to $59,999.99 94 14.1% 82 14.2% 
$60,000 to $79,999.99 64 9.6% 56 9.7% 
$80,000 or more 141 21.2% 117 20.2% 
Missing 45 6.8% 42 7.3% 
No. of Medications 
1 – 2 83 12.5% 60 10.4% 
3 – 4 165 24.8% 139 24.0% 
5 – 6 165 24.8% 143 24.7% 
7 – 8 108 16.2% 97 16.8% 
9 – 10 55 8.3% 50 8.6% 
> 10 67 10.1% 69 11.9% 
Missing 23 3.5% 21 3.6% 
Health Insurance 
Medicare 388 56.6% 339 49.5% 
Medicaid 71 10.4% 66 9.6% 
Private 424 61.9% 364 53.1% 
Uninsured 37 5.4% 33 4.8% 
Tricare 9 1.3% 6 0.9% 
Don’t know 7 1.0% 6 0.9% 
Missing 4 0.6% 4 0.6% 
Health Status Excellent 20 3.0% 16 2.8% 
 Very Good 169 25.4% 137 23.7% 
Good 265 39.8% 229 39.6% 
Fair 171 25.7% 158 27.3% 
Poor 39 5.9% 37 6.4% 
Missing 2 0.3% 2 0.3% 
1
7
6
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APPENDIX B
 Table 2 
Comparative effectiveness of the MNAS with contemporary scales 
Scales R2 
Std. Reg. 
Coef. 
p value 
Concurrent Period 
MNAS 0.04 -0.21 <0.01 
5-point 1986 Morisky Scale 0.02 -0.13 <0.01 
MAR-Scale 0.02 -0.12 <0.01 
Predictive Period 
MNAS 0.08 -0.29 <0.01 
AE 0.01 -0.10 0.02 
1
7
8
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* Adherence Estimator is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 
Whitehouse Station, NJ, USA. US and non-US Patents Pending. Copyright © 2008 Merck Sharp and Dohme Corp., 
a subsidiary of Merck & Co., Inc. All rights reserved. 
† This was done to ensure that patient identifiers were not exposed to the researchers, and to abide with Health 
Insurance Portability and Accountability Act (HIPAA)62 regulations. 
‡ Each month was assumed to be 30 days long. 
§ This categorization was based on that proposed by McHorney28, where a score is ‘0’ is categorized as ‘low risk for 
adherence problems’, ‘2-7’ as ‘medium risk for adherence problems’, and ‘8+’ as ‘high risk of adherence problems’. 
** This model was also run specifying the categorized Adherence Estimator® score as a categorical variable in the 
model. This resulted in an R2 of 0.03. 
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OVERVIEW 
 
The purpose of this chapter is to discuss the findings and implications of this dissertation. 
First, results of reliability and validity testing of the Medication Non-Adherence Scale (MNAS) 
and the Medication Non-Persistence Scale (MNPS), and suggestions for their use in health care 
practice, will be elaborated. Following this, limitations of the methodology used here, and some 
directions for future research, will be discussed. This chapter will end of a brief conclusion for 
this dissertation project. 
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KEY FINDINGS AND SUGGESTIONS FOR USE IN HEALTH CARE PRACTICE 
 
Medication Non-Adherence Scale 
The primary goal of this dissertation was to develop a health care practice setting 
administrable, disease non-specific scale for medication non-adherence that can distinguish 
between different reasons for non-adherence. Such a scale would not only have the ability to 
estimate concurrent medication non-adherence, but also future non-adherence. The results 
presented in this document offer evidence for the achievement of these goals. Six and three 
month adaptations of the National Committee for Quality Assurance (NCQA) proportion of days 
covered (PDC) measure1 were used as criterion measures to concurrently and predictively 
validate the MNAS. The NCQA PDC measure is recommended, and used, by certain payers to 
enhance reimbursement to health care practitioners. Thus based on the ability of this scale to 
estimate PDC, if used in the practice setting, the MNAS may allow practitioners to identify 
patients that need medication adherence management, improve their performance measures, and 
thus enhance their reimbursement from payers2. A confirmatory factor analysis showed that the 
MNAS can be divided into five sub-scales that offer reasons for the non-adherence – intentional 
non-adherence due to worries about side-effects, intentional non-adherence due to worries about 
addiction, intentional non-adherence due to worries about cost, intentional non-adherence due to 
lack of perceived need for the medication, and unintentional non-adherence. The scores obtained 
on these sub-scales can be used by health care practitioners to implement appropriate
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interventions to improve their patients’ medication adherence, and thus also reimbursement from 
payers. 
 The MNAS is a sixteen item scale, measured on a five-point scale with options ‘Never’. 
‘Rarely’, ‘Sometimes’, ‘Often’, and ‘Always’, scored from 1 through 5. If a patient presents with 
a summated score of more than 16 on the scale, the person administering the scale must study the 
responses on individual items to identify potential reasons for non-adherence. Such a score may 
indicate a PDC of less than 95% in the past 6 months. A summated score of greater than 20 on 
the scale may indicate a higher propensity of non-adherence in the next three months (i.e. a PDC 
of less than 95%) as well. In order to improve medication adherence, appropriate interventions 
should then be implemented based on the patient’s performance on the sub-scales. 
 Besides demonstrating good psychometric properties, the MNAS was also seen to 
perform better than some of the currently used medication adherence and medication adherence 
propensity scales. Specifically, this dissertation compared the concurrent PDC estimating ability 
of the MNAS with the five-point variant of the 1986 Morisky scale3–6 and the Medication 
Adherence Reasons Scale (MAR-Scale)3,4, and its predictive PDC estimating ability against the 
Adherence Estimator® (AE)7. Based on our results, the MNAS outperformed all of these scales 
in estimating the criterion measures considered. 
 
Medication Non-Persistence Scale 
This dissertation also aimed at developing a multi-item self-reported measure for 
medication non-persistence. The evidence presented in this document outlines a successful 
endeavor. This process was exploratory in nature, as based on our literature review, currently 
there are no multi-item instruments that help identify reasons for non-persistence. A series of 
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both, qualitative and quantitative, pretest were conducted to arrive at a set of items for this scale. 
A confirmatory factor analysis revealed a single factor solution for the Medication Non-
Persistence Scale (MNPS). In its final version, the MNPS is a nine item scale, designed to obtain 
binary ‘yes’ or ‘no’ responses on each item. Each ‘yes’ response receives a score of ‘1’, and each 
‘no’ response a score of ‘0’. The MNPS was validated against a standardized patient-specific 
mean days to discontinuation measure. The result of a ROC curve analysis concluded that a 
summated score greater than zero may indicate non-persistence. If such a score is obtained, the 
person administering the scale must inspect the individual items to identify the reason(s) for non-
persistence. 
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LIMITATIONS OF THE STUDY AND DIRECTIONS FOR FUTURE RESEARCH 
 
 The first limitation of this study is potentially low external validity. The study was 
conducted among patrons of three independent community pharmacies in the Southeastern 
United States, thus potentially limiting its generalizability to other socio-demographic and 
geographic populations. Future research should apply the MNAS and the MNPS in a variety of 
settings to test their external validity. This will further strengthen the evidence for reliability, 
validity, and applicability of the scales. 
 The MNAS underwent multiple rounds of qualitative and quantitative pretests. But the 
amount of variation explained in the concurrent PDC measure was observed to be low (5.87%). 
Based on the results of Pretest 3 in Paper 1, the likelihood of observing this result due to socially 
desirable response bias seems unlikely. This may have been observed because of a missing factor 
in the scale; medication non-adherence is not only comprised of under-dosing, but also over-
dosing. Most scales, including the MNAS, only assess under-dosing.* Future research should 
address this aspect of non-adherence by adding a factor that measures over-dosing, and identifies 
reasons for the same. This may help improve the amount of variation explained in the concurrent 
measurement of PDC. 
 The results of tests for studying concurrent and predictive validity of the MNAS 
indicated that current medication-taking behavior may help predict future medication-taking 
behavior. This may indicate that medication adherence has certain trait-like aspects. But a lot of
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the variation in future medication-taking behavior (about 89%) was not explained by the MNAS. 
Such a result may indicate presence of state- or occasion-like factors within the construct. Future 
research should study the work published by Cole and colleagues in their development of the 
Trait-State-Occasion Model8 and the Latent Trait-State-Occasion Model9, and apply it to the 
context of medication adherence. 
 A scale developed for use in the clinical practice setting should ideally be short to 
administer. Though the MNAS offers more functionality, better psychometric properties, and 
more effective estimation of the PDC than some of the contemporary scale (e.g. 1986 Morisky 
scale10, Morisky Medication Adherence Scale11, MAR-Scale3, the Adherence Estimator®7, etc.), 
it is longer than most scales currently used in practice. Its length may increase the burden on the 
person administering the survey (e.g. pharmacist, pharmacy technician, nurse, etc.). Future 
researchers should make an attempt at developing a ‘short-form’ version of the MNAS to reduce 
administration times. 
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CONCLUSIONS 
 
 Despite the strong evidence for detrimental effect of medication non-adherence and non-
persistence12–16, there are quite a few issues with the effective measurement of these constructs in 
clinical practice. There are no multi-item instruments to measure medication non-persistence in 
clinical practice today. Paper 1 presented evidence for the reliability and validity of such an 
instrument – the Medication Non-Persistence Scale (MNPS). Besides estimating days to 
discontinuation, and helping identify individuals who may have discontinued their medication in 
the past year, the MNPS items also offer reasons for the discontinuation. 
There are numerous instruments available to measure medication adherence, but some 
instruments do not possess good psychometric properties (e.g. 1986 Morisky scale10), some offer 
different factor structures across diseases (e.g. MAR-Scale3), some use different scales for a part 
of their items (e.g. RAM scale17), while some require the patients to remember minute details 
about the medications that they are taking (Diagnostic Adherence to Medications Scale 
(DAMS)18. The Medication Non-Adherence Scale (MNAS) has been designed to be disease non-
specific, and relatively easy to administer in a practice setting. Paper 1 demonstrated evidence 
for its internal consistency reliability, convergent, discriminant and concurrent validity, and 
ability to distinguish between five reasons for medication non-adherence – worries about side-
effects, worries about addiction to the medication, worries about medication cost, lack of 
perceived need for the medication, and unintentional non-adherence. Paper 2 offered evidence
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for its ability to predict future medication non-adherence. Moreover, the MNAS has been 
concurrently and predictively validated against adaptations of the National Committee for 
Quality Assurance (NCQA) proportion of days covered (PDC) measure1. This measure is used 
by the Centers for Medicare and Medicaid Services (CMS), and some private payers, to 
determine health care quality and reimbursement.2 Paper 3 concluded that the MNAS was more 
effective in estimating concurrent PDC as compared to the 1986 Morisky scale5,6,10 and the 
MAR-Scale3, and future PDC as compared to the AE7. Thus, the MNAS is a worthy candidate 
for an instrument to identify cases of medication non-adherence, predict its future occurrence, 
and distinguish between reasons for non-adherence, in a clinical practice setting. 
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 and equipment patent searches; write reports on market potential for new chemical 
 moieties. 
 With the Department of Pharmacy Administration: 
 Collaborate with faculty in assessing issues like medication non-adherence, primary 
 medication non-adherence (PMN), etc. 
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Teaching Assistant, School of Pharmacy, UM, MS (August 2011 – December 2011; August 
2012 – December 2012): 
 Assist in teaching the Information Skills in Pharmacy Practice (PRCT 350) course. 
Project Associate (Intern), BioVid Corporation, Princeton, NJ (May 2011 – August 2011): 
 Assist researchers in conducting primary and secondary pharmaceutical market research, 
i.e., analyzing physician and patient survey, patient record and IMS data, creating project 
report presentations, etc. 
Research Fellow, CPMM, UM, MS (June 2010 – May 2011): 
 Collaborate with faculty to study the impact of various clinical and health policy issues 
on health and economic outcomes using Medicare and Medicaid health insurance claims 
data. 
Summer Intern, NuMed Labs, Pvt. Ltd, Vasai, Maharashtra, India (May 2007 – August 2007) 
 Obtain a general overview of the operations in a pharmaceutical company. 
 
Research Experience 
Athavale AS, Banahan BF III, Bentley JP, West-Strum DS, Antecedents and consequences of 
 pharmacy loyalty behavior, International Journal of Pharmaceutical and Healthcare 
 Marketing; 2015;Vol.9,Iss.1 
Athavale AS, Null KD, Banahan BF, Clark J, Defining specialty drugs: an environmental scan 
 and comparison of specialty drug lists, Academy of Managed Care Pharmacy 26th 
 Annual Meeting and Expo, Tampa, FL, 1-4 April, 2014 
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Athavale AS, Banahan BF III, Hardwick SP, Clark JP, Are you counting prescription medication 
 utilization correctly? International Society for Pharmacoeconomics and Outcomes 
 Research Annual International Meeting, Washington, DC, 2-6 June, 2012 
Datar M, Athavale AS, Banahan BF III, Multiple sclerosis and depression: a case-control study 
 among  Medicare beneficiaries, Annual Drug Information Association Meeting, Chicago, 
 IL, 19-23 June 2011 
Athavale AS, Banahan BF III, Mendonca CM, Impact of potential drug-drug interactions (DDIs) 
 on health outcomes and cost to Medicaid: the monetary benefits of quality health care, 
 International Society for Pharmacoeconomics and Outcomes Research Annual 
 International Meeting, Baltimore, MD, 21-25 May 2011 
Dharmarajan S, Yang Y, Athavale AS, Bentley JP, Null KD, Banahan BF III, Risk of 
 hospitalization for pneumonia associated with the use of atypical versus typical 
 antipsychotics in a national sample of Medicare beneficiaries, International Society for 
 Pharmacoeconomics and Outcomes Research Annual International Meeting, 
 Baltimore, MD, 21-25 May 2011 
Dharmarajan S, Yang Y, Athavale AS, Bentley JP, Null KD, Banahan BF III, Risk of hip 
 fractures in elderly Medicare beneficiaries using atypical or typical antipsychotics: a 
 propensity score analysis, International Society for Pharmacoeconomics and Outcomes 
 Research Annual International Meeting, Baltimore, MD, 21-25 May 2011 
Dharmarajan S, Yang Y, Athavale AS, Bentley JP, Null KD, Banahan BF III, Risk of 
 hospitalizations for venous thromboembolism in atypical vs. typical antipsychotic users 
 in a national sample of Medicare beneficiaries: a claims data analysis, International 
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 Society for Pharmacoeconomics and Outcomes Research Annual International Meeting, 
 Baltimore, MD, 21-25 May 2011 
Banahan BF III, Mendonca CM, Athavale AS, Bentley JP, Incidence and outcomes of potential 
 drug-drug interactions between ACE/ARBs and potassium sparing diuretics, International 
 Society for Pharmacoeconomics and Outcomes Research Annual International Meeting, 
 Atlanta, GA, 15-19 May 2010 
Athavale AS, Lokhandwala TT, Datar MV, West-Strum DS, An analysis of FDA untitled and 
 warning letters, 2009-2012, The Pharmaceutical Marketing Research Group Institute 
 Meeting, Jersey City, NJ, 20-22 October, 2013 
Athavale AS, Bentley JP, Banahan BF III, Thinking longitudinally: adding the fourth dimension 
 to your research, The Pharmaceutical Marketing Research Group Institute Meeting, 
 Philadelphia, PA, 14-16 October, 2012 
Bentley JP, Adcock KG, Dikun JA, Athavale AS, Do pharmacy students read exam instructions? 
 American Association of Colleges of Pharmacy Annual Meeting, Kissimmee, FL, 14-18 
 July, 2012 
Athavale AS, Banahan BF III, Bentley JP, West DS, Identification of patient loyalty segments 
 (PLSs) in development of marketing strategies for pharmacies, American Pharmacists 
 Association Annual Meeting, Seattle, WA, 25-28  March 2011 
Athavale AS, Lokhandwala T, Padwal T, Verma S, Jariwala K, Banahan BF III, Holmes ER, 
 Comparing patients’ compliance attitudes and behaviors with their perceived value for 
 RxSync ServiceSM components, American Pharmacists Association Annual Meeting, 
 Washington, DC, 11-15 March 2010 
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Verma S, Athavale AS, Lokhandwala T, Padwal T, Jariwala K, Banahan BF III, Holmes ER, An 
 assessment of perceived value and willingness to pay for RxSync ServiceSM, American 
 Pharmacists Association Annual Meeting, Washington, DC, 11-15 March 2010 
 
Awards and Honors 
Graduate School Dissertation Fellowship, Graduate School, UM, MS (August 2014) 
Full Scholarship for Graduate Education, Center for Pharmaceutical Marketing and Management 
 and the Department of Pharmacy Administration, UM, MS (August 2008 – July 2014) 
Graduate Students Council Research Grant recipient, UM, MS (June 2014) 
Platinum award for podium presentation at the Academy of Managed Care Pharmacy’s 26th 
 Annual Meeting & Expo, Tampa, FL, 1-4 April, 2014 
Contributor at the Poster Session, The Pharmaceutical Marketing Research Group Institute 
 Meeting, Jersey City, NJ, 20-22 October, 2013 
Contributor at the Poster Session, The Pharmaceutical Marketing Research Group Institute 
 Meeting, Philadelphia, PA, 14-16 October, 2012 
International Society for Pharmacoeconomics and Outcomes Research Distinguished Service 
 Award (June 2012) 
Who’s Who Among Students in American Universities & Colleges® (January 2012) 
Research Fellowship, CPMM, University of Mississippi, University, MS (June 2010 – May 
 2011) 
Inducted into Rho Chi – The Academic Honors Society in Pharmacy (April 2010) 
